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ABSTRACT 
 
Antimicrobial peptides (AMPs), known also as host defense peptides, are fundamental 
evolutionarily conserved components of innate immunity. Constitutively or inducibly expressed in 
response to invasion by pathogens, they operate synergistically with other defence molecules to 
combat infections. Despite differences in their size and sequence, many of them share a net positive 
charge at neutral pH, and fold into amphipathic structures, often after contact with bacterial 
surfaces. HDPs are attractive alternative candidates for antibiotic treatment, because they offer 
several advantages over the currently used drugs. They combat pathogens by targeting bacterial 
membranes, thus impairing essential membrane-related functions, and, in some cases, also target 
intracellular components. Due to their peculiar mechanism, the resistance towards these peptides 
would be difficult for the bacteria to develop. Several proteins, including proteins apparently not 
involved in immunity, can behave as sources of HDPs hidden in their primary structures and 
released by the action of host and/or bacterial proteases. Recently it has been developed a 
bioinformatic tool allowing to identify such “cryptic HDPs”. Analyzing a library of 4000 proteins, 
we have identified and studied several novel cryptic HDPs from human and plant. Among these, 
three human peptides (GVF27, ApoBS and ApoBL) show pharmacologically relevant properties 
like significant antimicrobial activity on a broad spectrum of bacteria (including some clinical 
isolates), very promising antibiofilm properties (both on pre-formed and attached biofilm), strong 
affinity for endotoxins as LPS and LTA and immunomodulatory properties on LPS induced murine 
macrophages, while two peptides from plant (IKY31 and IKY23) are strong anti-biofilm agents and 
not toxic against eukaryotic cells. Overall our data suggest that these new cryptic HDPs, could serve 
as leads for the design of innovative antimicrobials with immunostimulating and 
immunomodulatory properties. 
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Riassunto 
 
I peptidi antimicrobici sono molecole naturali multifunzionali prodotte in vari 
organismi. La maggior parte di queste molecole sono cationiche e per questo anche note come 
cationic Host Defence Peptides (cHDPs), effettori del sistema immunitario innato che 
contribuiscono alla rapida eliminazione di agenti patogeni come batteri o funghi. In aggiunta alla 
loro attività antimicrobica e antifungina, i cHDPs sono anche in grado di modulare la risposta 
immunitaria. Questi peptidi possono agire direttamente o indirettamente, inducendo in modo 
selettivo la produzione di chemochine in cellule del sistema immunitario e il reclutamento di altre 
cellule immunitarie al sito di infezione. Questa particolare combinazione di attività 
farmacologicamente interessanti e lo sviluppo sempre più frequente del fenomeno di resistenza agli 
antibiotici tra i batteri patogeni, rendono i cHDPs un'alternativa molto valida agli antibiotici 
convenzionali. Alcuni cHDPs sono già in fase II / III di trial clinico. Il mio progetto di dottorato è 
stato incentrato sull’identificazione e caratterizzazione di nuovi cHDPs, ponendo particolare 
attenzione sia alla loro attività antimicrobica sia alla verifica della loro potenziale capacità di 
bloccare l’eccessivo effetto pro-infiammatorio di endotossine come l’LPS dei batteri Gram negativi 
o l’LTA dei Gram positivi. Recentemente, è stato sviluppato un sistema bioinformatico atto 
all'identificazione di proteine (cHDPs -Releasing Proteins) che possono contenere, ed 
eventualmente liberare, potenziali peptidi antimicrobici nascosti nella loro struttura primaria. Tale 
metodo si basa sul calcolo della carica netta, idrofobicità e lunghezza del peptide e permette una 
previsione semi-quantitativa della sua attività antimicrobica. Utilizzando tale metodo e consultando 
banche dati di proteine sia umane sia vegetali, diversi nuovi cHDPs criptici sono stati identificati e 
alcuni di questi sono stati oggetto di studio durante il dottorato.  
GVF27, ad esempio, è un cHDP identificato nella proteina HSD-3 umana. Tale proteina 
appartiene a una famiglia di deidrogenasi che agisce in maniera NADP- dipendente. L’analisi 
dell’attività antimicrobica di GVF27, ottenuta analizzando un ampio pannello di ceppi batterici sia 
Gram negativi sia Gram positivi e confrontata a quella della catelicidina da pollo CATH-2, ha 
confermato che questo peptide è un forte agente antimicrobico. Il potere antimicrobico di GVF27 è 
stato analizzato anche in presenza di concentrazioni fisiologiche di cationi bivalenti ottenendo con 
ciò un risultato piuttosto interessante se si considera che tali condizioni in genere sono inattivanti 
per la maggior parte dei peptidi antimicrobici. Allo scopo di investigare più approfonditamente 
l’attività antimicrobica di GVF27, è stato allestito inoltre un saggio in grado di valutare il livello di 
ATP extracellulare di due colture batteriche (Escherichia coli ATCC 25922 e Staphylococcus 
aureus multiresistente WKZ-2). I risultati ottenuti da tale saggio indicano chiaramente che GVF27 
ha un meccanismo di azione di tipo litico. Ulteriori analisi hanno evidenziato che GVF27 possiede 
anche proprietà antibiofilm. Infatti è stato osservato che GVF27 è in grado sia di inibire la 
formazione del biofilm sia di destrutturare biofilm preformati. In entrambi i casi analizzati inoltre 
va sottolineato che GVF27 conserva il suo potere citotossico nei confronti dei batteri incapsulati 
nella matrice del biofilm. Generalmente i peptidi antimicrobici cationici posseggono un particolare 
vantaggio che è quello della selettività di membrana per cui, essendo carichi positivamente, 
interagiscono preferenzialmente con le membrane cariche negativamente dei batteri piuttosto che 
con quelle eucariotiche (per lo più zwitterioniche). A tal riguardo sono stati allestiti esperimenti per 
verificare la potenziale tossicità di GVF27 su diverse linee cellulari e murine. I risultati ottenuti 
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evidenziano che GVF27, nonostante la sua spiccata tossicità per le cellule microbiche, non presenta 
alcun effetto tossico (anche a dosi superiori alle MIC) sulle cellule eucariotiche analizzate. Sono 
stati inoltre effettuati anche saggi di emolisi somministrando GVF27 a eritrociti di topo. Anche in 
questo caso è stata verificata l’assoluta non tossicità del peptide. Come descritto in precedenza, 
molti peptidi antimicrobici ricoprono anche un ruolo immunomodulante. Molti di questi infatti 
appartengono al sistema del complemento che permette il riconoscimento dei batteri patogeni dalle 
cellule del sistema immunitario. Altri invece attenuano risposte immunitarie eccessive che 
potrebbero portare a shock settici. In tale contesto, è risultato quindi opportuno investigare le 
eventuali proprietà immunomodulatorie di GVF27 attraverso esperimenti di ELISA e saggi di 
Griess condotti su macrofagi murini pre-trattati con LPS (endotossina specifica dei Gram negativi) 
e successivamente trattati con GVF27 oppure su macrofagi trattati con una miscela LPS/peptide 
hanno permesso di rilevare che il peptide in tutte le condizioni analizzate è in grado di attenuare 
significativamente sia la secrezione di Interleuchina-6 sia la produzione di ossido nitrico (NO), 
entrambi mediatori dell’infiammazione. Questi dati supportano l’idea che GVF27 possa interagire e 
bloccare l’LPS. Tuttavia sono stati condotti anche ulteriori esperimenti in cui le cellule era prima 
trattate con GVF27 e poi con LPS. Sorprendentemente, anche in questo caso il GVF27 è riuscito ad 
attenuare l’infiammazione indotta dall’LPS, in maniera indipendente dall’interazione diretta con 
questa molecola. Ulteriori evidenze, riguardo le proprietà immunomodulatorie di GVF27, sono state 
recentemente raccolte. I macrofagi sono cellule specializzate nella fagocitosi di agenti patogeni e 
nella loro digestione intracellulare. Tuttavia sono noti alcuni patogeni intracellulari che sono in 
grado di eludere i processi di digestione nei fagolisosomi. In questo caso è necessario che il 
potenziale antibatterico del macrofago venga incrementato e tale processo, può essere indotto grazie 
a segnali extracellulari, primo tra tutti l’IFN-γ. Questo meccanismo prende il nome di attivazione 
del macrofago e risulta difficoltosa in pazienti con carenza di IFN-γ o del suo recettore. Pertanto, 
oltre alle sopracitate attività anti-infiammatorie di GVF27, si è voluto anche indagare se il peptide 
presentasse la capacità di aumentare l’attività di macrofagi murini in seguito alla fagocitosi di un 
batterio. A tal riguardo è stato allestito un esperimento nel quale macrofagi murini pre-trattati con 
GVF27 sono stati successivamente incubati con il batterio Salmonella enterica serovar 
Thypimurium ATCC 14028. Al termine dell’incubazione, dopo aver eliminato mediante antibiotici 
tutti i batteri extracellulari, i macrofagi sono stati lisati ed è stata valutata la crescita dei batteri 
ancora vitali. In tal modo è stato possibile valutare il contributo di GVF27 all’uccisione 
intracellulare dei batteri fagocitati. Da tale esperimento è emerso che GVF27 è in grado di 
incrementare l’attività microbicida dei macrofagi in maniera dose dipendente. Inoltre, da dati 
pregressi in letteratura e da predizioni in silico emerge che anche le apolipoproteine umane sono 
fonte di peptidi bioattivi. L'apolipoproteina B è l'apolipoproteina principale dei chilomicroni, delle 
particelle VLDL, IDL e LDL ed è responsabile del trasporto di molecole di grasso, compreso il 
colesterolo, intorno al corpo (all'interno delle cellule esterne dell'acqua) a tutte le cellule di tutti i 
tessuti. Utilizzando il metodo bioinformatico sopra citato, sono stati identificati due nuovi HDP 
criptici nell'Apolipoproteina B (residui 887-922): chiamati ApoBL e ApoBS, rispettivamente di 38 
e 26 residui amminoacidici. È stato dimostrato che entrambi gli HDP sono dotati di un'attività 
antimicrobica ad ampio spettro e al contempo non mostrano né effetti tossici né emolitici verso le 
cellule eucariotiche. Oltre all’attività citotossica su cellule planctoniche, è interessante notare che 
per entrambi gli HDP è stata evidenziata anche un'importante attività anti-biofilm. I due peptidi 
infatti, quando sono stati saggiati sul biofilm formato da E. coli ATCC 25922, S. aureus MRSA 
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WKZ-2, P. aeruginosa ATCC 27853 e P. aeruginosa PAO1 presentano attività sia nei confronti del 
biofilm preformato sia durante la sua formazione, conservando in tutti i casi le proprietà puramente 
antibatteriche. Allo scopo di potenziare l'efficacia antimicrobica dei peptidi identificati da ApoB, 
nella prospettiva di un loro eventuale utilizzo terapeutico, si è deciso di allestire analisi denominate 
di terapia combinata, coadiuvando simultaneamente peptidi anti batterici e antibiotici in diverse 
combinazioni. Uno dei test più noti per valutare il sinergismo tra due composti è il cosiddetto 
esperimento "chequerboard" in cui viene utilizzata una serie bidimensionale di concentrazioni 
seriali di composti di prova come base per il calcolo di un indice di concentrazione inibitoria 
frazionaria (FIC) per dimostrare che combinazioni accoppiate di agenti possono esercitare effetti 
inibitori che non derivano semplicemente dalla somma degli effetti dei singoli componenti.  Tutte le 
combinazioni testate si sono dimostrate efficaci, sia con effetti addizionali sia sinergici tra peptidi e 
antibiotici.  Sui medesimi peptidi sono state condotte anche analisi di dicroismo circolare. Entrambi 
i peptidi tendono ad acquisire una conformazione specifica in presenza di SDS, TFE e LPS, mentre 
in acqua risultano destrutturati. Tale dato suggerisce che questi cHDPs, a contatto con le cellule 
batteriche, potrebbero adattarsi in prossimità delle membrane prima di agire su di essa, sia nel caso 
di un’azione destrutturante sia per essere trasportati all’interno della cellula. Va sottolineato inoltre 
che, in maniera analoga a GVF27, entrambi i peptidi derivanti da ApoB sono in grado di mitigare la 
produzione di interleuchina-6 e di ossido nitrico nei macrofagi murini indotti da LPS. Infine, 
risultati preliminari ottenuti su cheratinociti umani, indicano che i peptidi identificati in ApoB 
presentano interessanti proprietà di wound healing (in particolare ApoBL). Complessivamente i dati 
raccolti su questi nuovi cHDPs, compreso il sopracitato GVF27, aprono prospettive interessanti su 
un loro uso terapeutico.  
Inoltre, già durante il mio primo anno di dottorato è stato identificato per frammentazione in 
bromuro di cianogeno e caratterizzato il primo peptide antimicrobico criptico nascosto in PD-L4, 
una proteina inattivante il ribosoma di tipo 1 (RIP) dalle foglie di Phytolacca dioica L. Le proteine 
RIP sono degli enzimi identificati in piante, funghi, alghe e batteri. Essi sono dotati di attività di N-
glicosilasica, che determina la scissione di un residuo adenino-specifico in un sito conservato del 
rRNA 28S, con conseguente inibizione della sintesi proteica. Grazie all’approccio bioinformatico 
precedentemente citato, sono stati identificati, nel dominio N-terminale di PD-L1 / 2, un ulteriore 
membro del pool di proteine RIP di tipo 1 di P. dioica, due nuovi HDP criptici. Questi due peptidi, 
qui denominati IKY31 e IKY23, non presentano tossicità per le cellule eucariotiche ma presentano 
al contempo un’attività antibatterica ad ampio spettro. Oltre all’azione antimicrobica, è stato anche 
verificato che entrambi i peptidi posseggono significative proprietà antibiofilm. Infatti sia IKY23 
che IKY31 sono in grado di destrutturare il biofilm prodotto da due ceppi Gram-negativi: Klebsiella 
pneumoniae e Pseudomonas aeruginosa. È stato verificato che i peptidi derivati da PD-L1/2 sono in 
grado di indurre una forte riduzione, dose dipendente, della biomassa del biofilm, di influenzare lo 
spessore del biofilm e, nel caso di IKY31, di interferire sull’adesione cellula/cellula, probabilmente 
interagendo componenti strutturali del biofilm. Inoltre, mediante analisi CD, è stato anche rilevato 
che entrambi i peptidi derivati da PD-L1/2 sono in grado di assumere conformazioni stabili sia in 
presenza di agenti che mimano la struttura della membrana (TFE e SDS) sia di componenti di parete 
batteriche extracellulari, come LPS e alginato. Nel complesso, i dati raccolti su questi due peptidi 
danno un'ulteriore rilevanza all'importanza dei peptidi criptici derivanti da proteine RIP 
nell'interazione ospite/patogeno, in particolare nelle condizioni indotte da batteri che formano 
biofilm.  
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1. Introduction 
 
1.1 The plague of the antimicrobial resistance  
 
Since Dr. Fleming discovered in 1928 the first antibiotic from the fungus Penicillium 
chrysogenum, several other antimicrobial agents have been discovered and much progress has been 
made in the host defence field. From this first evidence, there was a widespread research of other 
new antibiotics with different targets: specific for one or few bacterial species or with a wide 
spectrum activity; intracellular activity directed on nucleic acids (quinolone, rifampicin), protein 
synthesis (tetracyclines, chloramphenicol) interfering with bacterial metabolism (sulfonamides, 
dapsone); directed on the cell wall (bacitracin, cephalosporins) or membrane (polymixins), specific 
or not for Gram negative (aminoglycoside) and positive (vancomycin) bacteria (figure 1). Their 
discovery should be considered, as well as the development of vaccines, one of the most influent 
reasons of the growth in human welfare [1].  
 
 
 
Figure 1. Mode of action of antibiotics (image adopted from [2]) 
 
However, even antibiotics have been shown their limits in their own properties. Nowadays, 
when common infections occur, antibiotics could easily eradicate them, but the healthy microbiota 
is seldom preserved, because of their multiplicity of target. This is a great disadvantage considering 
the positive role a healthy microbiota has on human health [3]. Moreover, antibiotics may cause 
side effects such as allergic reactions due to individual sensitivity to one or more components, 
toxicity to various organs or intolerance caused by interaction with other drugs. The abuse of drugs 
can lead to death. 
Among these, major problems could be carried by the antibiotic resistance.  
Antibiotic resistance was reported to occur when a drug loses its ability to inhibit bacterial 
growth effectively so that those bacteria become ‘resistant’ and continue to multiply in the presence 
of therapeutic levels of the antibiotics [4]. Generally, antibiotic resistance can occur as a natural 
selection process where nature empowers all bacteria with some degree of low-level resistance and 
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that is the reason why non-judicial use of antibiotic, in both biomedical and agricultural fields, is 
responsible for making microbes resistant [5]. The Center for Disease Control and Prevention 
(CDC) reported that 1.7 million people were nosocomially infected in hospitals in 2002 and 
99,000 deaths were occurring annually in the United States due to drug-resistant microbes [6]. 
Antibiotics fight to eliminate bacteria. But, bacteria tend to have a natural process that 
encourages resistance due to the exposure to antibiotics themselves. The resistance process can 
occur via gene level mutations. Antibiotics induce selective pressure and the genes act in 
association with selective pressure to favour bacteria that have gained the resistance, which results 
in a selective advantage. For example, β-lactam antimicrobial agents is the most common treatment 
for bacterial infections and continues, paradoxically, to be the prominent cause of resistance to β-
lactam antibiotics among Gram-negative bacteria worldwide. The persistent exposure of bacterial 
strains to a multitude of β-lactams has induced dynamic and continuous production and mutation of 
β-lactamase genes in these bacteria, expanding their activity even against the newly developed β-
lactam antibiotics [7]. Moreover, bacteria possess the ability to directly transfer genetic material 
between each other by transferring plasmids, this behaviour signifies that natural selection is not the 
only mechanism by which resistance evolves, but their mutual transformation could be a process of 
resistance amplification. Development of resistance may also likely occur if users fail to take their 
full course of prescribed antibiotic treatment. Bacteria subsequently remain untouched gaining more 
strength against the antibiotics. In this way, bacteria may collect multiple resistance traits over time 
and can become resistant to multiple classes of antibiotics [8]. Obviously, bacterial genetical 
resistance is translated in a protein-mediated system to avoid the mechanism of action: modifying 
their targets, enzymatically inactivating or eliminating antibiotics by efflux pumps. Different 
mechanisms of the common drug resistance are shown in Table 1 [4].  
 
 
 
Table 1. Table representing the mechanism of drug resistance of common antibiotics (image adopted from 
[4]. 
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Unfortunately, resistance has increasingly become a problem in recent years because the 
pace at which we novel antibiotics are discovered has slowed drastically now, while antibiotic use is 
rising. And it is not just a problem confined to bacteria, but all microbes, including parasites, fungi 
and viruses, that have the potential to mutate and render our drugs ineffective [9]. According to the 
prevision of deaths attributable to antimicrobial resistance every year compared to other major 
causes of death in 2050, victims of the ineffectiveness of antibiotics will be more numerous than 
those of cancer as shown in figure 2 [10]. 
 
 
 
Figure 2. Death due to AMR (AntiMicrobial Resistance) estimate in 2050 compared to mortalities caused 
by other major illnesses [10]. 
 
All these considerations have shown how mandatory the development of new antimicrobial 
molecules is and the importance of a constant renovation which had lead the scientific community 
to point their interest on alternative and new molecules e.g. antimicrobial peptides (AMPs) which 
are considered as an alternative to conventional drugs [11].  
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1.2 From antimicrobial peptides to host defence peptides (HDPs) 
 
Antimicrobial Peptides (AMPs), are small molecules consisting of 12-50 amino acids with a 
positive net charge widely diffused in most living organisms. Peptides with biological activity have 
been isolated from a high number of organisms belonging to both plant and animal kingdoms such 
as bacteria, plants, insects, amphibians and mammals. The skin of numerous species of amphibians, 
for example, has proved to be a rich source of peptides (bombesin, magainin, temporin, etc.), 
products and secretions from granular glands in response to a variety of stimuli [12]. In humans and 
in other mammals (like mouse, rat or rabbit), antimicrobial peptides belonging to the defensin 
family are stored as granules in neutrophils (blood cells specializing in phagocytosis), while 
polymorphonucleated leukocytes of bovine animals are rich in peptides belonging to the family of 
cathelicidins that demonstrated significant antimicrobial activity in vitro and in vivo. 
AMPs play a very important role in so-called innate or natural immunity, consisting of a 
series of non-specific defense mechanisms, that is, directed towards a wide spectrum of 
microorganisms and present in an individual since birth. These are pre-existing to exposure to 
foreign substance (antigen) and represent the first true defense barrier of the organism from the 
pathogens [13]. It has been shown that some peptides exhibit strong antimicrobial activity against 
both Gram-positive and Gram-negative bacteria, fungi and are also capable to inhibit the replication 
of some viruses [14]. The mechanism of action of most AMPs is due to the alteration of cell 
membranes following interaction between the peptide and membrane structures. The effects that 
can be achieved in this interaction are: disorganization of membrane structure, alteration of 
permeability, leakage of cytoplasmic components and lysis of the cell. Some peptides, such as 
buforin interact directly with intracellular targets (DNA and / or RNA) by inhibiting vital cell 
functions. Moreover, other AMPs (e.g. peptides derived from cathelicidins and defensins) act as 
demonstrated in recent years with a mechanism independent from direct microbial killing; in fact, in 
the presence of pathogenic agents they can act inhibiting the host's proinflammatory response and / 
or stimulate immune defense reactions, for this reason they are better named host defense peptides 
(HDP) [15]. Biological features of these molecules justify the interest in the scientific community 
as innovative and alternative therapeutic agents, especially in infections sustained by antibiotic-
resistant microorganisms. 
 
 
1.3 Features of host defense peptides 
 
HDPs are usually produced as pre-pro-peptides of about 60-170 amino acids. When 
they are released they are cut into their mature form due to the action of specific proteases.  HDPs 
vary considerably in size and secondary structure, but they have common characteristics including 
that most of these peptides are cationic and amphipatic. The specificity of HDPs for bacterial 
membranes is based on the differences in charge and lipid composition between membranes of 
prokaryotic and eukaryotic cells. The membrane of eukaryotic cells is rich in zwitterionic lipids, 
while that of prokaryotic cells is rich in negative charged lipids that can interact with cationic HDPs 
[16]. Cationic HDPs are divided into four subgroups on the basis of their amino acid composition 
and structure: (i) α-helical peptides, linear peptides enriched for specific amino acids (e.g. proline 
and arginine), (ii) peptides prone to form stable β-sheets stabilized by one or more disulfide bridges, 
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(iii) loop peptides with a single disulfide bridge; and (iv) peptides without a well-defined structure 
[17]. Cationic HDPs generally are small and contain 12–50 amino acids, with 2–9 positively 
charged lysine or arginine residues, and up to 50% hydrophobic amino acids. For these reasons, 
they tend to form amphipathic structures in the hydrophobic environment, characteristics that allow 
peptides, in contrast to conventional antibiotics, to interact with microbial membranes through not 
only electrostatic but also hydrophobic interactions [18]. In this manner, they can destroy bacterial 
membrane normal functions by forming ion channels or pores, dissolving the membrane as if they 
were detergents, or causing damages in the membrane itself.  
 
 
1.4 Mechanisms of action 
 
In the following paragraph some of the major mechanisms of action are described of host 
defense peptides: 
 
a. Direct bacterial killing 
b. LPS neutralization 
c. Intracellular targets 
d. Opsonization and intracellular killing 
 
 
Direct bacterial killing 
 
As already mentioned, HDPs have been also named host defense peptides for their 
involvement into immune system regulation and immune response modulation [15]. However, some 
peptides act, simply and directly, killing the target. This kind of peptides could be clustered in two 
big groups: peptides that have their target on the surface of bacteria or in their cytoplasm. Most of 
the peptides that act on the surface of bacteria form pores on this surface. Several models that 
particularly address the actions of defensins and linear amphiphilic cationic peptides propose 
formation of channels through and/or disruption of bacterial membranes [19].  
Killing of bacteria via pore formation in the bacterial membrane requires three principal 
steps: binding to the bacterial membrane, aggregation within the membrane, and formation of 
channels. The channel formation leads to leakage of internal cell contents, e.g. ATP molecules, and 
cell death [20].   
An HDP must cross the negatively charged outer wall of Gram-negative bacteria, which 
contains lipopolysaccharides (LPS), or the outer cell wall of Gram-positive bacteria, which contains 
acidic polysaccharides. The three well-established models for pore formation are the barrel-stave 
pore, the toroidal pore, and the carpet model (figure 3): 
 
1) Barrel stave model: multimers of HDP cross the cell membrane so that the hydrophobic 
part is facing the lipid bilayer and the hydrophilic part is facing the lumen of the pore. The 
assembled peptides form barrel-like channels resembling staves; 
2) Toroidal pore: the HDP form a monolayer by connecting the outer and inner lipid layers in 
the pore; 
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3) Carpet model: in this model peptides first cover the outer surface of the membrane like a 
carpet and then act like detergents, disrupting the membrane bilayer after reaching a 
threshold concentration. The pores are formed from micelle-like units.  
 
 
 
 
Figure 3. A. the barrel-stave pore; B. the thoroidal pore; C. the carpet model. (the image is by [19]) 
 
 
Intracellular targets 
 
There is increasing evidence for intracellular targeting of microbes as both alternative 
and synergistic pathways to membrane rupture and cell lysis [23]. The HDP buforin II, possessing a 
linear proline hinge and containing an amphipathic α-helical peptide, has been proven to translocate 
across the cell membrane without loss of the transmembrane potential and with intracellular 
contents intact even at five times the MIC. Cellular function of Escherichia coli is inhibited by 
accumulation of buforin II in the cytoplasm and via binding to DNA and RNA [24]. Some HDPs 
such as indolicidin have been demonstrated to penetrate bacterial cell membranes rendering them 
relatively undamaged but with antibacterial activity achieved by inhibition of RNA, DNA and 
protein synthesis [25]. Other hypotheses for intracellular action include stimulation of the autolytic 
enzyme cascade. Cationic HDPs, for example lactoferrin and lysozyme, may mimic the action of β-
lactam antibiotics and activate autolytic cell wall enzymes such as muramidases causing 
bacteriolysis [26]. Intracellular targeting of protein synthesis by degradation of proteins required for 
DNA replication has been shown to be a primary mechanism of action for indolicidin and the pig 
intestinal peptide PR-39. Further, apidaecin and oncocin inhibit protein translation in bacteria by 
binding to and inactivating the 70S ribosome and Bac7(1-35) accumulates within Escherichia coli 
to high concentrations and inhibits protein synthesis by binding to the ribosome [27]. 
 
LPS neutralization 
 
LPS is one of the most studied targets of HDPs for their ability to neutralize or 
modulate the aggregation of this endotoxin. LPS is a major component of the outer leaflet of the 
outer membrane in Gram-negative bacteria. LPSs consist of an O-specific chain that is highly 
variable in different bacterial strains, a core oligosaccharide, and lipid A. LPSs are essential for 
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bacterial growth and viability, but macrophages stimulated by LPS induce the release of pro-
inflammatory cytokines (TNF-α, IL-1 and IL-6) into the blood, resulting in septic shock [21]. 
Accordingly, LPSs are excellent target for HDPs because they have the potential to both directly 
inhibit the growth of multidrug-resistant bacteria and to neutralize the action of released LPS due to 
its stimulation of immune cells. HDPs generally bind to LPS through electrostatic interactions 
between their cationic amino acids (Lysine and Arginine) and head groups of LPS, and this 
complex is stabilized through hydrophobic interactions between the hydrophobic amino acids of the 
peptide and fatty acyl chains of LPS [22].  
 
 
Opsonization and intracellular killing 
 
The first line of defense of the organism by pathogens is represented by the epithelial 
barrier. Damages of this barrier facilitate host invasion by pathogens and the initiation of an 
infection process to which the body responds to the inflammatory state through immune system 
cells. Resolving inflammation requires the cooperation of many cellular components of the immune 
system, such as lymphocytes, T helper cells, neutrophils, natural killer cells (NK) or macrophages 
[28]. Macrophages are immune system cells specializing in the phagocytosis of infected, dead or 
tumorous eukaryotic cells, as well as pathogens such as viruses, parasites, or bacteria. Many of the 
HDPs are secreted as inactive pro-peptides from neutrophils, macrophages or epithelial cells and 
enzymatically activated to release the active form that is able to interact with the pathogen 
membrane. This interaction could promote the recognition of bacteria by the macrophages 
(opsonization) encouraging their phagocytosis and the follow eradication of the pathogen. LL37 is 
the most know human HDPs that is able to act as an opsonins [29]. 
After the phagocytosis, digestion of pathogens follows mediated by intracellular factors and 
vesicle acidification into the phagolysosomes. Normally, a macrophage is able to complete 
phagocytosis and bacterial clearance alone, but some pathogens of clinical relevance can 
chronically infect the macrophage by inactivating it. In fact, there are various mechanisms 
developed by bacteria to survive the intracellular environment of macrophages by inhibiting, for 
example, lysosomal fusion or acidification necessary for the activation of lysosomal proteases, or 
even invading the cell cytoplasm or further they can change their own outer membrane structure or 
decrease their negative charge to avoid cationic HDP effectiveness [30]. All these mechanisms can 
lead the macrophage to death. In order to avoid this process, the immune system developed a known 
counterfeit such as macrophage activation. This activation is carried out by type 1 T helper cells 
(TH1), which secrete additional activator signals that increase the antimicrobial capacity of the 
macrophages by allowing them to destroy intracellular pathogens. Activated macrophages become 
effective cells with powerful antibacterial activity: they more effectively blend the lysosomes with 
phagocytes, produce radical forms of oxygen and nitric oxide (NO), but also HDPs and proteases 
that can attack extracellular and intracellular pathogens. The reason why macrophages are normally 
in an inactivated state is that activated state requires greater energy consumption and increased 
macrophage aggression due to nitric oxide, protease or oxygen radicals toxicity. This would cause a 
danger to the healthy tissue of the host.  
Among the signal molecules necessary for the activation of macrophages there are the IFN-γ 
and the ligand of CD40, a receptor present on the macrophage membrane. Patients with genetic 
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diseases that determine IFN-γ deficiency, or its receptor, fail to control infections due to 
intracellular pathogens. Activation of macrophages induces increased CD40 and TNF-α receptors 
expression and promotes TNF-α production. This autocrine stimulus has a synergistic effect with 
IFN-γ secreted by TH1 cells in increasing the bactericidal action of the macrophage. All these 
signals lead to macrophage sensitization increasing their phagocytic activity and inner antimicrobial 
systems, however, not only these signals are able to activate it. For example, Crotamin is a peptide 
that has been discovered to stimulate macrophagic phagocytosis [31]. This process can also be 
triggered by small amounts of LPS or, as recently reported, by HDPs like LL37 alone or complexed 
with DNA [32]. Since some bacterial strains, like Salmonella enterica or Staphylococcus aureus are 
able to actively invade epithelial cells, intriguingly, has been also reported that HDPs, like temporin 
B, could defend these cells from invasive bacteria [33]. To note, as it is possible to activate 
macrophages, they may also be inhibited by anti-inflammatory factors, such as IL-10 secreted by 
TH2 cells. 
 
 
1.5 Cryptic host defense peptides and their in silico identification 
 
Some bacterial strains have acquired a limited resistance to HDPs by producing specific 
proteases [34]. To overcome this resistance, multicellular eukaryotes secrete “HDP-Releasing 
Proteins” (HDP-RPs) which release active peptides only after a partial proteolytic processing 
operated by bacterial and/or host proteases. Therefore, a bacterial strain producing defense 
proteases against HDPs “commits suicide” by triggering itself the release of “cryptic” HDPs from 
their precursors. This mechanism has been indeed demonstrated for Zf-3, a ribonuclease from 
Danio rerio [35]. Several proteins can be considered as HDP-RPs. Lysozyme is a well-known 
example in this sense as it exerts bactericidal action by hydrolyzing peptidoglycan but, if 
inactivated by proteolysis, it releases HDPs [36, 37]. Mammalian's lactoferrin, a multifunctional 
protein, owns bactericidal determinants at the N-terminus. Its proteolysis in infants’ stomach leads 
to the release of peptides, which are more bactericidal than the corresponding native protein on 
several strains, including antibiotic-resistant strains [38, 39]. Human thrombin, a key enzyme in the 
coagulation cascade, bears bactericidal determinants in the C-terminal region [40, 41]. Other 
interesting examples of cryptic HDPs can be seen in several heparin-binding domains [42], growth-
factors [43, 44] and chemokines [45]. 
Fast bioinformatic approaches highlighted the presence of putative antimicrobial regions 
that could be extremely useful for the discovery of new cryptic host defence peptides. Pane et al. 
[46] developed an efficient strategy to identify potential HDP-RPs and to locate antimicrobial 
fragment(s) hidden into their amino acidic sequence. This method also allows a semi-quantitative 
prediction of the antimicrobial activity and, due to the inclusion of some strain-specific variables, 
could be fine-tuned to predict efficacy on specific bacterial strains. This method assigns to any 
given peptide an antimicrobial score, known as “absolute score” (AS), based on net charge, 
hydrophobicity and length of the peptide and of two bacterial strain-dependent weight factors 
defining the contribution of charge and hydrophobicity to the antimicrobial activity. To analyse a 
protein potentially bearing hidden antimicrobial regions, the AS values of all the peptides of the 
desired length contained in a precursor protein can be plotted as a function of peptide sequence and 
length, thus obtaining an accurate map of the antimicrobial activity determinants.  
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This method has been recently used to identify two novel HDPS in the sequences of an 
archaeal transcription factor [47] two human apolipoproteins [48, 49], a human putative 
dehydrogenase [50], a type 1 ribosome inactivating protein (RIP) from Phytolacca dioica L. [51] 
and other different proteins, some of which described in this thesis. 
 
1.6 Aim of this thesis 
 
Due to the extreme necessity of new antibiotics, lately HDPs have decisively sparked 
research interest thanks to their successful properties like the multifunctional role, ductility in 
formulation and therapeutic application [52].   
Aim of this thesis was to report a wide characterization of six new cryptic HDPs from 
human and plants identified in silico by Professor Ennio Notomista [46]. This thesis concerns 
GVF27 [50], a peptide identified at the C-terminus of four isoforms of human 11-hydroxysteroid 
dehydrogenase-1 β-like; two peptides from human Apolipoprotein B [49] and three peptides from 
type 1 ribosome-inactivating proteins (RIPs) from leaves of Phytolacca dioica L., one from the 
protein PD-L4 [51] and two from the protein PD-L1/2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
 References 
 
1. Dane Lyddiard, Graham L. Jones, Ben W. Greatrex; Keeping it simple: lessons from the 
golden era of antibiotic discovery, FEMS Microbiology Letters, Volume 363, Issue 8, 1 
April 2016, https://doi.org/10.1093/femsle/fnw084. 
2. Bbosa, G., Mwebaza, N., Odda, J., Kyegombe, D. and Ntale, M. (2014) 
Antibiotics/antibacterial drug use, their marketing and promotion during the post-antibiotic 
golden age and their role in emergence of bacterial resistance. Health, 6, 410-425. 
doi: 10.4236/health.2014.65059. 
3. Belkaid Y, Hand T. Role of the Microbiota in Immunity and inflammation. Cell. 
2014;157(1):121-141.; Homeostatic Immunity and the Microbiota Yasmine Belkaid1,2, * 
and Oliver J. Harrison1; doi:10.1016/j.cell.2014.03.011. 
4. Zaman SB, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A Review on Antibiotic 
Resistance: Alarm Bells are Ringing. Muacevic A, Adler JR, eds. Cureus. 2017;9(6):e1403. 
doi:10.7759/cureus.1403 
5. Levy S.B. (1992) From Tragedy the Antibiotic Age is Born. In: The Antibiotic Paradox. 
Springer, Boston, MA 
6. Klevens RM, Edwards JR, Richards CL Jr, Horan TC, Gaynes RP, Pollock DA, Cardo 
DM, Estimating health care-associated infections and deaths in U.S. hospitals, 2002. 
Public Health Rep. 2007 Mar-Apr; 122(2):160-6.] 
7. Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. Antibiotic resistance and extended 
spectrum beta-lactamases: Types, epidemiology and treatment. Saudi Journal of Biological 
Sciences. 2015;22(1):90-101. doi:10.1016/j.sjbs.2014.08.002.) 
8. Avorn J, Barrett JF, Davey PG, et al Antibiotic resistance: Synthesis of recommendations by 
expert policy.  
9. The Review on Antimicrobial Resistance, 2014, Chaired by Jim O’Neill 
10. Premanandh J, Samara BS, Mazen AN. Race Against Antimicrobial Resistance Requires 
Coordinated Action – An Overview. Frontiers in Microbiology. 2015;6:1536. 
doi:10.3389/fmicb.2015.01536.) 
11. Lloyd DH. Alternatives to conventional antimicrobial drugs: a review of future prospects. 
Vet Dermatol 2012; 23: 299–304 
12. Enrico König, Olaf R.P. Bininda-Emonds, Evidence for convergent evolution in the 
antimicrobial peptide system in anuran amphibians, In Peptides, Volume 32, Issue 1, 2011, 
Pages 20-25, ISSN 0196-9781, https://doi.org/10.1016/j.peptides.2010.10.009 
13. Wang G. Human Antimicrobial Peptides and Proteins. Pharmaceuticals. 2014;7(5):545-594. 
doi:10.3390/ph7050545. 
14. Jenssen H, Hamill P, Hancock REW. 2006. Peptide antimicrobial agents. Clin Microb Rev 
19:491–511. 10.1128/CMR.00056-05. 
15. Otvos, L., Jr. Immunomodulatory effects of anti-microbial peptides. Acta Microbiol. 
Immunol. Hung. 2016, 63, 257–277 
16. Lee TH, Hall KN, Aguilar MI. Antimicrobial Peptide Structure and Mechanism of Action: 
A Focus on the Role of Membrane Structure. Curr Top Med Chem. 2016;16(1):25-39. 
Review. 
16 
 
17. Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415(0028–0836 
(Print)):389–395.) 
18. Huang Y, He L, Li G, Zhai N, Jiang H, Chen Y. Role of helicity of α-helical antimicrobial 
peptides to improve specificity. Protein Cell. 2014;5(8):631-42. doi: 10.1007/s13238-014-
0061-0.) 
19. Pálffy R, Gardlík R, Behuliak M, Kadasi L, Turna J, Celec P. On the physiology and 
pathophysiology of antimicrobial peptides. Mol Med. 2009 Jan-Feb;15(1-2):51-9. doi: 
10.2119/molmed.2008.00087 
20. Jean-François F, Elezgaray J, Berson P, Vacher P, Dufourc EJ. Pore Formation Induced by 
an Antimicrobial Peptide: Electrostatic Effects. Biophysical Journal. 2008;95(12):5748-
5756. doi:10.1529/biophysj.108.136655.) 
21. Gutsmann T, Müller M, Carroll SF, MacKenzie RC, Wiese A, Seydel U.Dual role of 
lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-
induced activation of mononuclear cells. Infect Immun. 2001 Nov;69(11):6942-50. 
22. Park S-C, Park Y, Hahm K-S. The Role of Antimicrobial Peptides in Preventing Multidrug-
Resistant Bacterial Infections and Biofilm Formation. International Journal of Molecular 
Sciences. 2011;12(9):5971-5992. doi:10.3390/ijms12095971.) 
23. Le C-F, Fang C-M, Sekaran SD. Intracellular Targeting Mechanisms by Antimicrobial 
Peptides. Antimicrobial Agents and Chemotherapy. 2017;61(4):e02340-16. 
doi:10.1128/AAC.02340-16. 
24. Xie Y, Fleming E, Chen JL, Elmore DE. Effect of proline position on the antimicrobial 
mechanism of buforin II. Peptides. 2011;32(4):677-682. doi:10.1016/j.peptides.2011.01.010 
25. Hsu C-H, Chen C, Jou M-L, et al. Structural and DNA-binding studies on the bovine 
antimicrobial peptide, indolicidin: evidence for multiple conformations involved in binding 
to membranes and DNA. Nucleic Acids Research. 2005;33(13):4053-4064. 
doi:10.1093/nar/gki725.) 
26. Ginsburg I, van Heerden PV, Koren E. From amino acids polymers, antimicrobial peptides, 
and histones, to their possible role in the pathogenesis of septic shock: a historical 
perspective. Journal of Inflammation Research. 2017;10:7-15. doi:10.2147/JIR.S126150. 
27. Wilson DN, Guichard G, Innis CA. Antimicrobial peptides target ribosomes. Oncotarget. 
2015;6(19):16826-16827. 
28. Clausen ML, Agner T. Antimicrobial Peptides, Infections and the Skin Barrier. Curr Probl 
Dermatol. 2016;49:38-46. doi: 10.1159/000441543.). 
29. Sol et. al. 2013. LL-37 Opsonizes and Inhibits Biofilm Formation of Aggregatibacter 
actinomycetemcomitans at Sub-bactericidal Concentrations.  
30. Susana Matamouros, Samuel I. Miller, S. Typhimurium strategies to resist killing by 
cationic antimicrobial peptides, Biochimica et Biophysica Acta (BBA) - Biomembranes, 
Volume 1848, Issue 11, Part B, November 2015, Pages 3021-3025, ISSN 0005-2736, 
https://doi.org/10.1016/j.bbamem.2015.01.013. 
31. Lee KJ, Kim YK, Krupa M, et al. Crotamine stimulates phagocytic activity by inducing 
nitric oxide and TNF-α via p38 and NFκ-B signaling in RAW 264.7 macrophages. BMB 
Reports. 2016;49(3):185-190. doi:10.5483/BMBRep.2016.49.3.271.) 
32. Tang X, Basavarajappa D, Haeggström JZ, Wan M. P2X7 Receptor Regulates 
Internalization of Antimicrobial Peptide LL-37 by Human Macrophages That Promotes 
17 
 
Intracellular Pathogen Clearance. The Journal of Immunology Author Choice. 
2015;195(3):1191-1201. doi:10.4049/jimmunol.1402845./ Stephan A, Batinica M, Steiger J, 
et al. LL37:DNA complexes provide antimicrobial activity against intracellular bacteria in 
human macrophages. Immunology. 2016;148(4):420-432. doi:10.1111/imm.12620.) 
33. Di Grazia A, Luca V, Segev-Zarko LT, Shai Y, Mangoni ML. Temporins A and B Stimulate 
Migration of HaCaT Keratinocytes and Kill Intracellular Staphylococcus 
aureus. Antimicrobial Agents and Chemotherapy. 2014;58(5):2520-2527. 
doi:10.1128/AAC.02801-13. 
34. M. Sieprawska-Lupa, P. Mydel, K. Krawczyk, K. Wojcik, M. Puklo, B. Lupa, P. Suder, J. 
Silberring, M. Reed, J. Pohl, W. Shafer, F. McAleese, T. Foster, J. Travis, J. Potempa. 
Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived 
proteinases. Antimicrob. Agents Chemother., 48 (2004), pp. 4673-4679 
35. Zanfardino, A., Pizzo, E., Di Maro, A., Varcamonti, M. and D’Alessio, G. (2010), The 
bactericidal action on Escherichia coli of ZF-RNase-3 is triggered by the suicidal action of 
the bacterium OmpT protease. FEBS Journal, 277: 1921–1928. doi:10.1111/j.1742-
4658.2010.07614.x 
36. H.N. Hunter, W. Jing, D.J. Schibli, T. Trinh, I.Y. Park, S.C. Kim, H.J. Vogel.  
The interactions of antimicrobial peptides derived from lysozyme with model membrane 
systems. Biochim Biophys. Acta, 1668 (2005), pp. 175-189 
37. H.R. Ibrahim, D. Inazaki, A. Abdou, T. Aoki, M. Kim. Processing of lysozyme at distinct 
loops by pepsin: a novel action for generating multiple antimicrobial peptide motifs in the 
newborn stomach. Biochim Biophys. Acta, 1726 (2005), pp. 102-114 
38. J.L. Gifford, H.N. Hunter, H.J. Vogel. Lactoferricin: a lactoferrin-derived peptide with 
antimicrobial, antiviral, antitumor and immunological properties. Cell Mol. Life Sci., 62 
(2005), pp. 2588-2598  
39. M. Sinha, S. Kaushik, P. Kaur, S. Sharma, T.P. Singh. Antimicrobial lactoferrin peptides: 
the hidden players in the protective function of a multifunctional protein. Int J. Pept., 2013 
(2013), p. 390230  
40. G. Kasetty, P. Papareddy, M. Kalle, V. Rydengard, M. Morgelin, B. Albiger, M. Malmsten, 
A. Schmidtchen. Structure-activity studies and therapeutic potential of host defense peptides 
of human thrombin. Antimicrob. Agents Chemother., 55 (2011), pp. 2880-2890  
41. P. Papareddy, V. Rydengard, M. Pasupuleti, B. Walse, M. Morgelin, A. Chalupka, M. 
Malmsten, A. Schmidtchen. Proteolysis of human thrombin generates novel host defense 
peptides. PLoS Pathog., 6 (2010), p. e1000857 
42. E. Andersson, V. Rydengard, A. Sonesson, M. Morgelin, L. Bjorck, A. Schmidtchen. 
Antimicrobial activities of heparin-binding peptides. Eur. J. Biochem., 271 (2004), pp. 
1219-1226  
43. R.P. Darveau, J. Blake, C.L. Seachord, W.L. Cosand, M.D. Cunningham, L. Cassiano 
Clough, G. Maloney. Peptides related to the carboxyl terminus of human platelet factor IV 
with antibacterial activity. J. Clin. Invest., 90 (1992), pp. 447-455;  
44. M. Malmsten, M. Davoudi, B. Walse, V. Rydengard, M. Pasupuleti, M. Morgelin, A. 
Schmidtchen. Antimicrobial peptides derived from growth factors. Growth Factors, 25 
(2007), pp. 60-70  
18 
 
45. L.T. Nguyen, H.J. Vogel. Structural perspectives on antimicrobial chemokines. Front 
Immunol., 3 (2012), p. 384  
46. Katia Pane, Lorenzo Durante, Orlando Crescenzi, Valeria Cafaro, Elio Pizzo, Mario 
Varcamonti, Anna Zanfardino, Viviana Izzo, Alberto Di Donato, Eugenio Notomista, 
Antimicrobial potency of cationic antimicrobial peptides can be predicted from their amino 
acid composition: Application to the detection of “cryptic” antimicrobial peptides, Journal 
of Theoretical Biology, Volume 419, 2017, Pages 254-265, ISSN 0022-5193, 
http://dx.doi.org/10.1016/j.jtbi.2017.02.012. 
47. Notomista E, Falanga A, Fusco S, et al. The identification of a novel Sulfolobus 
islandicus CAMP-like peptide points to archaeal microorganisms as cell factories for the 
production of antimicrobial molecules. Microbial Cell Factories. 2015;14:126. 
doi:10.1186/s12934-015-0302-9. 
48. K. Pane, V. Sgambati, A. Zanfardino, G. Smaldone, V. Cafaro, T. Angrisano, E. Pedone, S. 
Di Gaetano, D. Capasso, E.F. Haney, V. Izzo, M. Varcamonti, E. Notomista, R.E.W. 
Hancock, A. Di Donato, E. Pizzo. A new cryptic cationic antimicrobial peptide (amp) from 
human apolipoprotein E with anti-bacterial activity and immunomodulatory effects on 
human cells. FEBS J. (2016) 
49. Rosa Gaglione, Eliana Dell'Olmo, Andrea Bosso, Marco Chino, Katia Pane, Flora Ascione, 
Francesco Itri, Sergio Caserta, Angela Amoresano, Angelina Lombardi, Henk P. Haagsman, 
Renata Piccoli, Elio Pizzo, Edwin J.A. Veldhuizen, Eugenio Notomista, Angela Arciello, 
Novel human bioactive peptides identified in Apolipoprotein B: Evaluation of their 
therapeutic potential, In Biochemical Pharmacology, Volume 130, 2017, Pages 34-50, ISSN 
0006-2952, https://doi.org/10.1016/j.bcp.2017.01.009. 
50. A. Bosso, L. Pirone, R. Gaglione, K. Pane, A. Del Gatto, L. Zaccaro, S. Di Gaetano, D. 
Diana, R. Fattorusso, E. Pedone, V. Cafaro, H.P. Haagsman, A. van Dijk, M.R. Scheenstra, 
A. Zanfardino, O. Crescenzi, A. Arciello, M. Varcamonti, E.J.A. Veldhuizen, A. Di Donato, 
E. Notomista, E. Pizzo, A new cryptic host defense peptide identified in human 11-
hydroxysteroid dehydrogenase-1 β-like: from in silico identification to experimental 
evidence, In Biochimica et Biophysica Acta (BBA) - General Subjects, Volume 1861, Issue 
9, 2017, Pages 2342-2353, ISSN 0304-4165, https://doi.org/10.1016/j.bbagen.2017.04.009. 
51. Pizzo Elio, Zanfardino Anna, Di Giuseppe Antonella M.A., Bosso Andrea, Landi Nicola, 
Ragucci Sara, Varcamonti Mario, Notomista Eugenio and Di Maro Antimo (2015), A new 
active antimicrobial peptide from PD-L4, a type 1 ribosome inactivating protein 
ofPhytolacca dioica L.: A new function of RIPs for plant defence?, FEBS Letters, 589, doi: 
10.1016/j.febslet.2015.08.018. 
52. de Souza Cândido E, e Silva Cardoso MH, Sousa DA, Viana JC, de Oliveira-Júnior NG, 
Miranda V, Franco OL. The use of versatile plant antimicrobial peptides in agribusiness and 
human health. Peptides. 2014 May;55:65-78. doi: 10.1016/j.peptides.2014.02.003. 
 
 
 
 
 
 
19 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
A new cryptic host defense peptide identified 
in human 11-hydroxysteroid dehydrogenase-
1 β-like: from in silico identification to 
experimental evidence. 
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2.1 Introduction 
 
In this chapter the characterization of a cryptic HDP is described. It is a 27 amino acids 
long peptide, identified in the C’ terminal region of the human 11-hydroxysteroid dehydrogenase-1 
β-like protein. This sequence has been named GVF27. Human 11-hydroxysteroid dehydrogenase-1 
β-like (also known as 11β-HSD3) (UniProtKB: Q7Z5J1, http://www.uniprot.org/uniprot/Q7Z5J1) is 
an uncharacterized protein, present in eight putative isoforms, whose have been produced 
experimental evidences just at a transcriptional level. From these data, it seems that transcripts are 
mainly expressed in brain and lung cells. One of these isoforms has been isolated from a human 
brain cDNA library and produced in heterologous form in Escherichia coli. In this work [1] authors 
demonstrate that the isoform b has the capability to catalyze the dehydrogenation of cortisol in the 
presence of NADP(+), but this is the only existing indication in this direction and, moreover, 11β-
HSD3 only poorly catalyzes conversion of cortisol to cortisone. To note, it predates the 
glucocorticoid receptor in evolution [2], presuming a primary function distinct from glucocorticoid 
biology [3] 
This putative enzyme is part of the short-chain dehydrogenase/reductase (SDR) family, that 
is a very large family of enzymes, most of which are NAD+ or NADP+ dependent oxidoreductases 
[4]. All the members of the family only have a residue identity level of typically 15–20%, but two 
motifs are highly conserved [5, 6]. 
Generally, HSD family members participate in the metabolism of steroids, prostaglandins, 
retinoids, aliphatic alcohols and xenobiotics. 11β-hydroxysteroid dehydrogenase catalyzes the 
interconversion of inactive glucocorticoids (cortisone in human, dehydrocorticosterone in rodents) 
and active glucocorticoids (cortisol in human, corticosterone in rodents). Two major isoenzymes 
belonging to this subfamily, 11β-HSD1 and 11β- HSD2, have been identified and widely 
characterized.  
11β-HSD1, also called “liver” type 11β-hydroxysteroid dehydrogenase acts mainly as a 
NADPH-dependent cortisone reductase [7]. The 11β-HSD1 gene is highly expressed in the liver, 
adipose tissue, bone and the brain [8, 9]. Its main function is activating glucocorticoids, but it is also 
expressed in the brain, with the highest levels found in the cerebellum, hippocampus, cortex, 
pituitary and hypothalamus; it plays an important role in human obesity and insulin resistance [7, 
10, 11]. 
11β-HSD2, the “kidney” type 11β-hydroxysteroid dehydrogenase, acts as an NAD+-
dependent cortisol dehydrogenase. The 11β-HSD2 gene is highly expressed in classical 
mineralocorticoid-selective target tissues such as kidney, colon and sweat glands [12, 13, 14, 15].  
Moreover, 11β-HSD2 expressed in human fetal brain acts to protect the developing nervous system 
from the deleterious consequences of glucocorticoid overexposure, but 11β-HSD2 is barely 
expressed in the human adult brain. Reductase activity of 11β-HSD1 increases local cortisol levels 
and leads to increased differentiation [16, 17]. The dehydrogenase activity of 11β-HSD2 decreases 
the availability of active cortisol thereby facilitating proliferation [18]. It was reported that 11β-
HSD2 is upregulated in different tumors which suggests that the inhibition of 11β-HSD2 activity 
can prevent the tumor from growing. These two enzymes have been deeply investigated, while 11-
hydroxysteroid dehydrogenase-1 β-like was only recently discovered and never thoroughly studied.  
Nevertheless, Huang et al. [1] revealed that the isoform b of 11β-HSD3 is highly expressed 
in the brain: in the cerebrum, hippocampal neurons, cerebellar glioma and meningioma. These 
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results suggest that 11β-HSD3 is a “brain type” hydroxysteroid dehydrogenase. 11β-HSD3 was a 
highly conserved protein during evolution. Its homologs were widely found in different species 
including animals and plants [19] Furthermore, the expression of 11β-HSD3 in lung cancer cell 
lines resulted to be upregulated and this effect suggests that the abnormal expression of 11β-HSD3 
in the lung maybe related to the development of lung cancer. To note, no evidences have been 
produced about the involvement of 11β-HSD3 in the host defense.  
As described in the Chapter 1, recently, the use of bioinformatic approaches has increased 
the possibility to highlight the presence of putative antimicrobial regions in proteins, thus 
representing an extremely useful tool for the discovery of new cryptic host defense peptides [20]. 
Indeed, analyzing a pool of human secreted proteins using the bioinformatic strategy developed by 
Professor Ennio Notomista [21], a region was identified rich in very high scoring peptides at the C-
terminus of four isoforms of human 11-hydroxysteroid dehydrogenase-1 β-like.  The region 
selected, named GVF27, corresponds to this local maximum plus the glycine residue located 
upstream the 26 residues. The glycine residue was included in the peptide as, according to [22], a 
glycine at the N-terminus of an HDP is favorable for the activity. 
In this chapter, GVF27 has been fully characterized describing its bactericidal properties 
against planktonic and sessile bacteria, its cytotoxic and anti-inflammatory effects on murine cells 
and its structural properties in the presence of mimic membrane agents and wall bacterial 
determinants, such as LPS and LTA. 
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2.2 Results  
 
2.2.1 Antibacterial activity and mechanism of action of GVF27  
 
The antibacterial effectiveness of synthetic GVF27 was determined by measuring its 
MIC values on a panel of Gram-negative and Gram-positive strains (Table 1). All GVF27 MIC 
values are comparable to those observed for control peptide chicken cathelicidin CATH-2 both on 
Gram-negative and Gram-positive strains (Table 1).  
In order to verify salt resistant properties of GVF27, MIC values were also determined in the 
presence of physiological amounts of divalent cations as CaCl2 and MgSO4 (0.265 g/L and 0.097 
g/L respectively). As shown in Table 2, MIC values determined in the presence of divalent cations 
were only slightly different to those obtained in NB, thus indicating that antimicrobial properties of 
GVF27 are not affected by the different experimental conditions tested.  
Moreover, an experiment was performed to detect GVF27 antimicrobial activity during time 
until 2 hours towards MRSA WKZ-2 and E. coli ATCC 25922. Colonies of the two strains were 
counted after the incubation with two doses of GVF27. When the killing rate of GVF27 was 
measured, none of the strains analyzed survived after 2 h at 10 M peptide doses (Figure 1).  
 
 
 
GRAM POSITIVE                                                              
STRAINS 
 
GVF27 
 
 
CATH-2
 
GRAM 
NEGATIVE                                                              
STRAINS 
 
GVF27 
 
 
CATH-2 
MIC values (μM) MIC values (μM) 
 
MRSA 
WKZ-2 
 
5 
 
10 
 
 
E. coli 
ATCC 25922 
 
10 
 
10 
 
B. globigii 
TNO BMO13 
 
5 
 
5 
 
P. aeruginosa 
ATCC 27853 
 
10 
 
10 
 
B. licheniformis 
ATCC 21424 
 
5 
 
20 
 
P. aeruginosa 
PAO1 
 
20 
 
20 
 
S. aureus 
ATCC 29213 
 
5 
 
10 
 
S. enteriditis 
706 RIVM 
 
 
10 
 
10 
 
Table 1. Minimum Inhibitory Concentration (MIC, M) values of GVF27 peptide, compared to those 
obtained for CATH-2, against a panel of Gram-positive and Gram-negative bacteria. Values were obtained 
from a minimum of three independent trials.  
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GRAM 
POSITIVE                                                              
STRAINS 
 
0.5X NB 
 
0.5X NB + 
cations 
 
GRAM 
NEGATIVE                                                              
STRAINS 
 
0.5X NB 
 
 
0.5X NB + 
cations
MIC values (μM) MIC values (μM) 
 
MRSA 
WKZ-2 
 
5 
 
10 
 
 
E. coli 
ATCC 25922 
 
10 
 
10 
 
B. globigii 
TNO BMO13 
 
5 
 
5 
 
S. enteriditis 
706 RIVM 
 
 
10 
 
40 
 
Table 2. Minimum Inhibitory Concentration (MIC, M) values of GVF27 peptide, tested in different media, 
against a panel of two Gram-positive and two Gram-negative bacteria. Values were obtained from a 
minimum of three independent trials.  
 
 
 
 
 
Figure 1: Antibacterial activity rate of GVF27, evaluated by colony count assay, against MRSA WKZ-2 and 
Escherichia coli ATCC 25922.  
 
One of the mechanisms through which HDPs kill bacterial cells is by forming pores into 
biological membranes, resulting in the leakage of small molecules [23]. We tried to collect data on 
the mechanism of the antibacterial activity of GVF27 by measuring ATP levels in the media in 
which bacterial cells are grown in the presence of the peptide. In fact, in bacterial cells intracellular 
ATP concentration is maintained constant and the release of ATP into the environment can be 
detected by chemiluminescence, which indicates the disruption of the cell membrane. Thus, we 
performed an assay to detect ATP leakage using two bacterial strains, E. coli and MRSA, treated 
with two different doses of GVF27 for 20 min. As shown in Figure 2 (panels A and B), the 
presence of ATP in the culture media is evident. Thus, we can confidently conclude that GVF27 has 
a lytic effect both on MRSA WKZ-2 and on E. coli cells, with MRSA WKZ-2 cells being 
particularly sensitive to the peptide. As it is shown in Figure 2, GVF27 induced in MRSA WKZ-2 
cells a release of 70% ATP at a concentration of 0.5 M. To obtain the same degree of ATP leakage 
in E. coli cells it was necessary to use a higher concentration of GVF27.  
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Figure 2: GVF27-induced ATP leakage in MRSA WKZ-2 (A) and Escherichia coli ATCC 25922 (B) after 
treatment with 0,5 or 2 μM of GVF27. The assays were performed in three independent experiments.  
 
 
2.2.2 Anti-biofilm properties of GVF27 
 
Bacteria mainly exist as multicellular aggregates embedded within a self-produced 
extracellular polymeric matrix. In this condition, known as biofilm, growing microbial cells are 
physiologically distinct from planktonic cells. As natural HDPs have emerged as promising anti 
biofilm candidates to be used as an alternative to conventional antibiotics, we evaluated if GVF27 is 
endowed with anti-biofilm activity by performing experiments on E. coli ATCC 25922 in BM2 
medium. E. coli was grown over-night, diluted in BM2 medium containing increasing 
concentrations of the peptide (from 0,125 to 32 μM), and then incubated for 24 h, at 37˚C to 
evaluate its effectiveness on the biofilm formation. Following incubation, the analysis of biofilm 
production by crystal violet staining revealed a dose-dependent inhibition of biofilm formation, 
with about 90% inhibition at the highest concentration of peptide tested (Figure 3A). We also 
collected data that would indicate that GVF27 peptide exerts a significant effect on biofilm 
attachment. To investigate this, we followed the experimental procedure described above with the 
only exception that bacterial cells were incubated with increasing concentrations of peptide for 4 h, 
at 37°C. Also in this case, we observed a dose-dependent inhibition of biofilm attachment, with 
almost total inhibition at 32 µM peptide concentration (Figure 3A). Interestingly, GVF27 was 
found to exert significant effects also on preformed biofilms. This was evaluated by incubating 
preformed biofilm with increasing concentrations of the peptide for 24 h, at 37°C. At the highest 
peptide concentration tested, we observed a significant (∼20%) reduction of the preformed biofilm 
(Figure 3A). 
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Figure 3: A. Biofilm inhibitory activity of GVF27 against E. coli strain in BM2 medium. The effects of 
increasing concentrations of GVF27 peptide were evaluated either on biofilm formation, biofilm attachment, 
or on pre-formed biofilm. Biofilm was stained with crystal violet and measured at 630 nm. Shown are mean 
+ SD values of three independent experiments. B. Effects of increasing concentrations of GVF27 peptide on 
the viability of E. coli ATCC 25922 bacterial cells inside the biofilm structure. Cell viability was assessed by 
colony counting assay and expressed as the percentage of viable bacterial cells in treated samples with 
respect to the control untreated sample. Shown are mean + SD values of three independent experiments. 
 
 
In all cases, we also evaluated the percentage of viable bacterial cells inside the biofilm by colony 
counting assay. We found (Figure 3B) an almost total reduction of bacterial viability when 32 M 
GVF27 was added prior to biofilm attachment, a significant reduction (90%) when it was added 
prior to biofilm formation and a reduction of about 50% when the peptide was tested on pre-formed 
biofilm.  
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2.2.3 Cytotoxicity assays of GVF27 on eukaryotic cells 
 
The promising interest in the use of HDPs stems from their selective action on bacterial 
cells. We thus studied the cytotoxic effect of GVF27 towards mouse macrophages and erythrocytes. 
The addition of increasing concentrations (from 0.6 to 40 μM) of GVF27 to mouse macrophages 
RAW cells 264.7 did not result, at 24 h of incubation time, in any significant reduction in cell 
viability (Figure 4A). The same peptide concentrations were tested also on mouse erythrocytes to 
detect any hemolytic activity of GVF27. As shown in Figure 4B, the peptide did not exert any lytic 
effect on mouse red blood cells, even at the highest concentration tested.  
 
 
 
Figure 4: Cytotoxicity of GVF27 on eukaryotic cells. A) Effect of GVF27 on the viability of mouse 
macrophages Raw 264.7. B) Hemolytic activity of GVF27 on mouse erythrocytes. In both experiments the 
mean values ± SD from three independent experiments run in triplicate are shown.  
 
 
The cytotoxicity of GVF27 was also measured against human keratinocytes (HaCat) and on human 
cervical cancer cells (HeLa). In all cases, no significant cytotoxicity was ever observed (data not 
shown). It should be underlined that GVF27 is toxic to bacterial cells at concentrations similar to 
that used in the cytotoxicity assays described above. This selective behavior is eligible for the 
perspective of a future in vivo application of GVF27. Moreover, it should be noted that all the 
experiments mentioned above were carried out after an incubation time of 24 h, since the analysis 
of GVF27 stability in serum indicated that peptide degradation was almost complete after 24 h 
(Table 3).   
 
 
 
 
 
 
 
 
 
 
Table 3. Analysis of serum stability of GVF27 by RP-HPLC (see Methods). 
Time (hour) Area % 
0 100 
1 63 
2 41 
3 30 
24 6 
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2.2.4 Conformational studies of GVF27: Circular Dichroism, Fluorescence and NMR. 
 
Structural analysis by CD spectroscopy provides a qualitative picture of the structural 
elements that are present in a given peptide. Far-UV CD spectra indicate that GVF27 is largely 
unstructured both in water and in 10 mM Hepes pH 7.4. On the contrary, it is structured in 40% 
TFE (Figure 5). This behavior can be observed also for other HDPs, all prone to assume a specific 
conformation when interacting with membrane-mimicking agents like TFE. Moreover, 
deconvolution data reported in Table 4, indicate that structured GVF27 adopts a predominant 
helical structure (approximately of ≈ 50%).  
 
 
Figure 5: Far UV CD of GVF27 in the presence of increasing concentrations of TFE. 
 
 
 -helical % -strand % coil 
GVF27 18.2 24.0 57.8 
GVF27 - 40 %TFE 52.6  7.2  40.2  
GVF27 - 0,4 mg/mL LPS from 
Pseudomonas aeruginosa 
strain 10 
30.8  18.6  50.6  
GVF27 - 0,4 mg/mL LPS from 
Pseudomonas aeruginosa 
strain KK27 
32.1  12.3  55.5  
GVF27 - LTA 0,4 mg/mL 33.0  19.5  47.5  
 
Table 4. Secondary structure content of GVF27, calculated by means of CDPRO program. 
 
To further characterize structural properties of GVF27, the interaction with LPS and LTA, 
the main constituents of the cell wall of Gram negative and positive bacteria, respectively, was 
analyzed. CD spectra in the presence of LPS isolated from two different P. aeruginosa strains 
(strain 10 and clinical isolate KK27 strain) are shown in Figure 6 (panels A and B).  
GVF27 spectrum in water has a minimum at around 205 nm, indicating that the peptide is in a 
disordered conformation. Instead, in the presence of LPS (Fig. 6A-B), the peptide spectra present 
two minima centered around 210 and 225 nm, suggesting that in both cases it is able to assume a 
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helical conformation upon interaction. The deconvolution data (Table 4) confirm that both LPSs 
induce a similar increase in the amount of helical structure (about 31-32%) but with slightly 
different amounts of beta and coil structure. 
CD spectra, acquired in the presence of LTA, (Figure 6C), showed a relatively flat shape minimum 
centered at 215 nm, due to the presence of significant amounts both of alpha and beta structures as 
shown by deconvolution data (Table 4).    
 
 
 
 
Figure 6: Far UV CD of GVF27 in the presence of increasing concentrations of LPS from P. aeruginosa 10 
(A), from P. aeruginosa KK27 (B) and of LTA from Staphylococcus aureus (C). 
 
C 
B 
A 
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Spectrofluorimetric data were also collected to investigate if the interaction of GVF27 with 
LPS and LTA could influence the tertiary structure of the peptide based on the presence in the 
sequence of three Trp residues (see Figure 7). Fluorescence spectra were recorded upon excitation 
at 280 nm and 295 nm and showed that the interaction of the peptide with LPS, LTA, and TFE 
results in a blue shift of the wavelength of the maximum of emission, indicating that GVF27 folds 
upon interaction with LPS or LTA, in agreement with CD data. However, in the presence of TFE a 
less marked effect was observed. 
 
 
 
 
Figure 7: Tryptophan fluorescence spectra for GVF27 in H2O and in the presence of TFE (40%), LPS (0,5 
mg/mL) and LTA (1 mg/mL). 
 
Moreover, a deeper investigation of the conformational preferences of peptide GVF27 was 
performed by NMR spectroscopy. NMR characterization of GVF27 was performed in TFE-d3/H2O 
30:70 (v/v) mixture at 298 K. Through this analysis, GVF27 was confirmed to have a helical 
conformation like showed in Figure 8.  
 
 
 
 
Figure 8: NMR structures of GVF27 in TFE-d3/H2O 30:70 mixture at 298 K A) Backbone superposition 
of the 20 energy-minimized structures and B) Ribbon model of a representative structure. 
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2.2.5 GVF27 assembles LPS aggregates 
 
Dynamic Light Scattering (DLS) is a well-known technique used to measure Brownian 
motion (diffusion) and size distribution of particles in solution. For this reason, DLS experiments 
were used to investigate whether peptide GVF27 may alter the size of micelles of LPS and LTA 
(above their critical micelle concentration). In both cases GVF27 displayed an associating action, 
promoting the formation of larger aggregates. In particular, the data indicate that LPS from 
Pseudomonas is poly-dispersed in solution with major size-populations having a hydrodynamic 
radius centered at about 40 nm (Figure 9). Incubation of LPS with GVF27 causes a shift of the 
average size of LPS micelles to a higher value centered at about 260 nm. On the other hand, when 
the peptide was incubated with LTA, a mean diameter of 100 nm of the aggregates was observed, 
indicating a weaker potency of GVF27 in associating LTA aggregates. 
It can be hypothesized that this aggregation action, already observed for other HDP [24], may be 
part of a LPS neutralization mechanism, inhibiting the interaction of LPS with its cell receptors, 
with the concomitant blocking of cytokine production and release [25].   
 
 
Figure 9: Effect of GVF27 on the structural organization of LPS or LTA micelles. Light scattering of 
LPS from P. aeruginosa 10 (top) or LTA (bottom) before and after incubation with the peptide. 
 
2.2.6 Anti-inflammatory properties of GVF27  
 
Data above would indicate that GVF27 is able to assume specific conformations in the 
presence of mimic membrane agents, LPS and LTA, as well as to induce aggregation of LPS, and to 
a lesser extent of LTA. As it has been already reported that several HDPs are able to mitigate up-
regulation of LPS-induced pro-inflammatory mediators and cytokines [26], it seemed interesting to 
verify if GVF27 could possess also putative anti-inflammatory properties. To collect data on 
possible anti-inflammatory properties of GVF27, nitric oxide production and interleukin Il-6 release 
in murine macrophages RAW264.7 treated with GVF27 and LPS were analyzed. Nitric oxide (NO) 
plays diverse roles in biological systems: it is a mediator of vasodilatation, platelet aggregation and 
neurotransmission, and regulates function, death and survival of various cell types including many 
of those involved in immunity and inflammation.  To study the effect of GVF27 on NO production 
in LPS induced RAW 264.7 cells, we performed three types of treatments: 1. medium containing 
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peptide alone (5 or 20 M) for an initial incubation of 2 h followed by addition of 50 ng/mL LPS 
from Salmonella Minnesota; 2. medium containing 50 ng/mL LPS for an initial incubation of 2h 
followed by addition of peptide (5 or 20 M); 3. medium containing a mixture of peptide (5 or 20 
M) and 50 ng/mL LPS. In all the cases, culture supernatants were collected after 24 h. As shown 
in Figure 10A, GVF27 exerts a strong dose-dependent attenuation of the production of NO when 
co-incubated with 50 ng/ml LPS. Conversely, when we performed a pre-incubation of RAW 264.7 
cells with peptide and subsequently we induced LPS infection, the effect of GVF27 on NO 
production was not significant (Figure 10A). Similarly, when RAW 264.7 cells were pre-incubated 
with LPS and subsequently treated with 5 or 20 M of GVF27, we revealed a slight dose dependent 
reduction of NO production (Figure 10A).  
Cytokines are small proteins (about 25 kDa) released by many cell types, usually after an 
activation signal, and they induce a response by binding specific receptors. IL-6 is a monomer 
produced by T cells, macrophages and endothelial cells. It is able to determine growth and 
differentiation of B and T cells, and the production of acute phase proteins, like C-reactive protein. 
When we analyzed by ELISA the effect of GVF27 on RAW 264.7 cells, following the same scheme 
observed in the NO production assay, we revealed a strong inhibitory effect exerted by the peptide 
on the secretion of IL-6 when the macrophages were co-incubated for 24 h with GVF27 (5 or 20 
M) and 50 ng/ml LPS (see Figure 10B). Moreover, we found that GVF27 was able to exert also a 
significant dose dependent protective effect on cells. Indeed, as shown in Figure 10B (on the 
center), when RAW 264.7 cells were pre-treated for two hours with 5 or 20 M GVF27 and then 
incubated for 24 h with 50 ng/ml LPS, it was possible to observe a limited secretion of IL-6. When 
cells, instead, were pre-incubated with LPS and then subjected to the action of the peptide (see 
Figure 10B – on the right), a slight secretion of IL-6 was revealed. This suggests that, although the 
incubation time with the endotoxin was too short, the peptide was still able to reduce the secretion 
of the analyzed interleukin. Collectively, these data indicate that GVF27 is able to exert an 
intriguing anti-inflammatory effect on LPS treated cells.   
 
 
Figure 10: (A) Effect of GVF27 on NO production in LPS induced mouse macrophages RAW 264.1. 
LPS extracted from Salmonella minnesota was assayed at a final concentration of 50 ng/mL. All experiments 
were carried out for an incubation time of 24 h. (B) Effect of GVF27 on IL-6 release in LPS induced 
mouse macrophages RAW 264.1 LPS extracted from Salmonella minnesota was assayed at a final 
concentration of 50 ng/mL. All experiments were carried out for an incubation time of 24 h. 
A B 
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Finally, the ability of GVF27 to bind LPS, was further confirmed by a different approach using the 
chromogenic LAL (Limulus amaebocyte lysate) assay [27]. Three different concentrations of 
GVF27 (6.25 - 12.5 – 25 μM) were incubated for 30 minutes at 37 °C with LPS from Escherichia 
coli 011:B4 following manufacturer instructions. As shown in Figure 11, a concentration of 12.5 
μM GVF27 was enough to neutralize about 40% of LPS whereas the presence of 25 μM GVF27 
completely neutralized LPS thus supporting the hypothesis that GVF27 might act in a dose-
dependent manner as a scavenger of Gram negative’s LPS (Figure 11). 
 
 
 
Figure 11: Neutralization LPS in the presence of GVF27. Peptide was incubated with the endotoxin (0.25 
units/ml) for 30 min and the amount of free endotoxin quantified by LAL assay (see methods). 
 
 
 
2.2.7 Intracellular killing 
 
As already mentioned in the introduction, macrophages are specialized cells in the 
phagocytosis of pathogens and their intracellular digestion. However, some intracellular pathogens 
can escape digestion in phagolysosomes [28]. To cope with these pathogens, the antibacterial 
potential of the macrophage must be increased. This process is named macrophages activation and 
it can take place through extracellular signals, i.g. with the IFN-γ. Such activation is difficult in 
patients with a deficiency in IFN-γ or its receptor, however, there are other signals that may trigger 
the macrophage, such as LPS of Gram negative bacteria. In this experiment, we wanted to 
investigate whether beyond the immune modulating activities already described for GVF27, there 
was also the capability to increase the activity of murine macrophages in the intracellular digestion 
of Salmonella enterica serovar Thypimurium ATCC 14028, as has been already demonstrated for 
other HDPs [29]. Raw cells were preliminarily treated with two different doses of GVF27 (1 and 10 
μM) for 2 hours. They were then infected with 1 x 108 CFU / mL of Salmonella enterica for 1 h. 
Subsequently, with the use of antibiotics for 1h, all the bacterial cells remaining in the extracellular 
environment were killed. Finally, the macrophages were lysed to release the bacterial cells still 
alive. These cells were then plated on LB-agar and the next day the intracellular killing percentage 
was evaluated (Figure 12). 
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Figure 12: Intracellular clearance of Salmonella enterica induced by GVF27 in murine macrophages. 
 
From this experiment, carried out 5 times, it was found that the lowest tested dose of the 
peptide was not sufficient to determine the macrophage activation, however at the concentration of 
10 μM of GVF27, this was able to reduce to the number of viable intracellular bacteria more than 
50 % with respect to untreated control. Further investigation should explain the mechanism through 
which GVF27 is able to kill intracellular bacteria in macrophages. Major hypotheses to explain 
these phenomena are (i) that the peptide could be taken up by the macrophage from the media into 
the cytoplasm and there exert its antimicrobial activity; otherwise (ii) the peptide could 
extracellularly activate the macrophage as well as act on other known paracrine signals.  
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2.3 Conclusions  
A number of human proteins, whose primary functions are not necessarily related to 
host defense, contain HDPs hidden inside their sequence. In 2017, Pane Katia et al. [21] have 
established a bioinformatic procedure through which it is possible to identify host defense peptides 
in precursor protein sequences and predict their strain dependent antimicrobial propensities. By 
using this tool to analyze about 4,000 human secreted proteins, a cryptic peptide has been identified 
in human 11-hydroxysteroid dehydrogenase-1 -like (accession number UniProtKB: Q7Z5J1), here 
named GVF27, with potent antimicrobial activity. The experiments described in this chapter 
confirm that GVF27 peptide exhibits antibacterial activities, with MIC values comparable to that of 
a well-studied cathelicidin [30], against a broad spectrum of both Gram-positive and -negative 
strains. Interestingly, its antibacterial properties are not limited to planktonic cells but are 
significant also on sessile bacteria forming biofilm. Indeed, here we provide evidences that GVF27 
inhibits biofilm formation, as well as it is able to eradicate existing mature biofilm in a dose 
dependent manner. In addition, GVF27 is also able to induce a strong reduction of viable sessile 
bacterial cells. This suggests that our peptide presents affinity for biofilm components, presumably 
extracellular DNA and/or polysaccharides, but also retains its ability to attack bacterial membranes 
due to its amphipatic properties. This clearly confers to the peptide a relevant potential as an anti-
biofilm agent alternative to conventional antibiotics, the latter being almost totally ineffective 
against microbes encapsulated in biofilm.  
A crucial point regarding the development of membranolytic antimicrobial therapeutics 
is that they must not destroy the membrane of mammalian cells. We showed here that, although 
endowed with antimicrobial activity, GVF27 displays virtually no hemolytic and cytotoxic activity 
on an assortment of murine and human cell lines. This implies that GVF27, probably due to its net 
positive charge composition, has evident high membrane selectivity towards bacterial cells but not 
mammalian cells.  
From a structural point of view, in agreement with the canonical properties of most 
HDPs, we verified by CD and NMR experiments that GVF27 is unstructured in aqueous buffer 
whereas it tends to assume a helical conformation in the presence of TFE. Moreover, NMR data 
clearly indicate that the spatial segregation of polar and apolar amino acids of GVF27 are on 
opposite faces oriented along the axis of a helical structure. This would indicate that GFV27 is able 
to assume an optimal conformation to effectively promote strong membrane association. Further 
tests by CD and light scattering have also allowed to highlight that the peptide is able to interact 
both with LPS and LTA, albeit in a less effective manner with the latter, thus suggesting that it can 
bind to the microbial surfaces via these wall determinants.  
The ability of GVF27 to interact with LPS has been also confirmed by different 
approaches, thanks to which it has been possible to show that the peptide is able to inhibit the pro-
inflammatory response. Indeed, GVF27 strongly down-regulates the release of NO and the 
production of IL-6 both in LPS pre-treated murine macrophages cells and upon co-administration of 
the peptide and the endotoxin. Moreover, it is worth noting that in murine macrophages treated with 
GVF27 and then subjected to LPS, a decrease of both NO and IL-6 was still detectable, thus 
suggesting also a protecting action for the peptide. GVF27 also demonstrated that this protecting 
action could be exerted by enhancing macrophages intracellular antimicrobial systems that act on 
phagocyted bacteria like Salmonella enterica. This opens an interesting scenario because GVF27 is 
a “hidden” peptide in a protein that, although not yet been characterized, could be constitutively 
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present under physiological conditions and able to release, by induced proteolysis, a fragment 
containing GVF27 in response to pathogen invasion. Our hypothesis is substantiated by an in silico 
prediction of peptides obtainable as a result of hydrolysis, which was carried out on the isoforms in 
which we identified GVF27 by simulating hydrolysis mediated by neutrophil elastase. Indeed, as 
shown in Figure 13, possible peptides released by hydrolysis are virtually superimposable to 
GVF27 and all have high antimicrobial scores, thus clearly supporting our idea that human proteins 
may fascinatingly be seen as active reservoirs of HDPs.   
 
 
Figure 13. In silico prediction, on the C-terminal region of the four isoforms in which we have identified 
GVF27, of hypothetical peptides released by cleavage mediated by human neutrophil elastase.  
 
For each putative peptide (#1, #2, #3 and #4) the antimicrobial score by using the bioinformatic 
procedure described in Pane et al 2017 [21] has also been calculated. In our opinion at least three 
mechanisms could be responsible for GVF27 immune-modulatory properties. First, GVF27 might 
modulate cellular response to pro-inflammatory mediators by acting as an endotoxin scavenger 
during initial steps of infection. In this case the peptide could bind to and neutralize the endotoxin 
directly. Second, GVF27 might reduce inflammatory dysfunction during immune response by 
interacting with membrane receptors, i.e CD14, that then would activate down regulation of 
different pro-inflammatory pathways. Third, endogenous GVF27, or internalized from paracrine 
cells, may contribute to attenuation of the inflammatory response by interacting with intracellular 
targets. Based on these hypotheses and on the evidences described in this chapter, it is indisputable 
that the existence of cryptic HDPs implies that innate immunity is more complex than usually 
believed and that the human proteome is an unexplored and essential source of bioactive agents. In 
conclusion, GVF27 may offer several advantages compared to other antimicrobial agents: (i) it is 
non-immunogenic given its human origin; (ii) specifically targets bacterial strains, (iii) is not 
hemolytic and contributes to enhance anti-inflammatory response without altering cell viability. 
Thus, we confidentially believe that structural, immunomodulatory and antimicrobial data of 
GVF27 presented in this work, could serve as leads for the design of human-specific therapeutics. 
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2.4 Experimental procedures 
2.4.1 Peptide synthesis 
Peptide GVF27 was manually synthesized using the fluorenylmethyloxycarbonyl 
(Fmoc) solid-phase strategy (0.1 mmol). Synthesis was performed on NovaSyn TGA resin (loading 
0.25 mmol/g), using all standard amino acids. The first amino acid was bound to the resin by 
treatment with Fmoc-Thr(tBu)-OH (5equiv)/MSNT (5 equiv)/MeIm (3.75 equiv) in DCM for 3 h. 
Fmoc protecting group was removed by reaction with 30% piperidine in DMF (3 × 10 min). The 
amino acids in 10-fold excess were pre-activated with HBTU (9.8 equiv)/HOBT (9.8 equiv)/DIPEA 
(10 equiv) in DMF for 5 min and then added to the resin suspended in DMF. The reaction was 
carried out for 1 h and coupling efficiency was assessed by the Kaiser test. The peptide was cleaved 
off the resin by treatment with a mixture of trifluoroacetic acid (TFA)/water/triisopropylsilane 
(95:2.5:2.5 v/v/v) for 3 h at room temperature. Resin was filtered, and crude peptide was 
precipitated with diethyl ether, dissolved in H2O/ACN solution, and lyophilized. The product was 
purified by preparative RP-HPLC on a Shimadzu system equipped with a UV−visible detector 
SPD10A using a Phenomenex Jupiter Proteo column (21.2 × 250 mm; 4 μm; 90 Å) and a linear 
gradient of H2O (0.1% TFA)/ACN (0.1% TFA) from 20%–80% of ACN (0.1%TFA) in 20 min at a 
flow rate of 20 mL/min. Identity and purity of the compound were assessed by LC/MS using an 
AGILENT Q-TOF LC/MS instrument equipped with a diode array detector combined with a dual 
ESI source and an Agilent C18 column (2.1 × 50 mm; 1.8 μm; 300 Å) at a flow rate of 200 μL/min 
and a linear gradient of H2O (0.01% TFA)/ACN (0.01% TFA) from 5%–70% of ACN (0.01% 
TFA) in 15 min.  
 
2.4.2 Antimicrobial activity assays 
Antimicrobial activity of GVF27 peptide was tested against Escherichia coli ATCC 
25922, MRSA WKZ-2 (methicillin-resistant Staphylococcus aureus), Salmonella enteriditis 706 
RIVM, Bacillus globigii TNO BM013, Bacillus licheniformis ATCC 21424, Staphylococcus aureus 
ATCC 29213, Pseudomonas aeruginosa PAO1, and Pseudomonas aeruginosa ATCC 27853. 
Bacteria were grown to mid-logarithmic phase in Muller Hinton broth (MHB) at 37°C. Cells were 
then diluted to 2 x 10
6
 CFU/ml in Difco 0.5X Nutrient Broth (Becton-Dickenson, Franklin Lakes, 
NJ) containing increasing amounts of GVF27 (0,6-40 µM). Starting from a peptide stock solution, 
two-fold serial dilutions were sequentially carried out, accordingly to broth microdilution method 
[31]. Following over-night incubation, MIC100 values were determined as the lowest peptide 
concentration responsible for no visible bacterial growth. Alternative antimicrobial assays to test 
salt resistant properties of GVF27 have been carried out following the same procedure described 
above and using 0.5X Nutrient Broth medium containing physiological concentrations of divalent 
cations as CaCl2 and MgSO4 (0.265 g/L and 0.097 g/L respectively). 
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2.4.3 Killing kinetics 
To assess the time point of bacterial growth inhibition, killing kinetics with GVF27 
were performed. Two different peptide concentrations (1 or 10μM GVF27) were incubated with 
mid-logarithmic (2× 10
6 
CFU/ml) E. coli ATCC 25922 or MRSA WKZ-2. At 1, 5, 10, 20, 30, 60 
and 120 min, 100 μl aliquots were taken and immediately plated on TSA. Additionally, 20μl 
aliquots were diluted 10- to 1,000-fold and again 100μl was plated. After 16h incubation at 37 °C 
the surviving bacteria were counted. 
 
2.4.4 ATP leakage measurements  
MRSA WKZ-2 and Escherichia coli ATCC 25922 were grown in Muller Hinton broth 
(MHB) at 37°C to mid-logarithmic phase. Bacteria were centrifuged, resuspended in 10 mM 
phosphate buffer pH 7.0 + 1:100 MHB and diluted to 2×10
7
 CFU/ml. From each diluted sample, 60 
μl of bacterial suspension were incubated with 60 μl peptide solution (0.5 or 2 μM) for 20 min at 
37°C. Samples were then centrifuged, the supernatant was stored at 4°C until further use, and the 
bacterial pellet was suspended in lysis buffer and further incubated at 100°C. Cell lysates were 
centrifuged and supernatants were kept on ice. Subsequently, both intra- and extracellular ATP 
levels were determined using the Roche ATP bioluminescence kit HS II (Roche Diagnostics 
Nederland B.V., Almere, the Netherlands), according to the manufacturer's protocols. 
 
2.4.5 Serum Stability Assays 
The proteolytic susceptibility of GVF27 peptide was determined in 50% (v:v) human 
serum (Lonza, Basel, Switzerland). Human serum was previously activated by cooling at 4°C, 
centrifugation at 13,000g for 5 min and incubation at 37°C for 10 min in order to eliminate the lipid 
fraction. Then, 250 µL of serum was added to a 250 µL of an aqueous solution of GVF27 at a 
concentration of 1 mg/mL. The mixture was incubated at 37°C and, after 1, 2, 3 and 24 h, samples 
(25 μL) were centrifuged at 13,000g for 5 min and the supernatant was added to 75 L of H2O 
containing 0.1% TFA and further centrifuged. Supernatants were finally analyzed by the analytical 
Agilent 1200 Series Liquid Chromatograph, equipped with a binary pump delivery system, robotic 
autosampler, column thermostat and multi-wavelength detector. An ET 250/8/4 Nucleosil 5-C18 
column Machery-Nagel column (300 x 4mm, 5µm) and a linear gradient of H2O 
(0.1%TFA)/CH3CN (0.1%TFA) from 5 to 70% of CH3CN (0.1%TFA) in 30 min at flow rate of 
1mL/min were employed. The experiment was run in duplicate. 
 
2.4.6 Anti-biofilm activity assays 
Escherichia coli strain ATCC 25922 was grown over-night in Muller Hinton broth 
(MHB) and then diluted to 1×10
8
 CFU/mL in BM2 medium containing increasing peptide 
concentrations (0.125-32 µM). Incubation with the peptide was carried out either for 4 h, in order to 
test peptide effects on biofilm attachment, or for 24 h, in order to test peptide effects on biofilm 
formation. When peptide effects on preformed biofilm were evaluated, bacterial biofilms were 
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formed for 24 h at 37 °C, and then treated with increasing concentrations of the peptide (0.125-32 
µM).  In all the cases, at the end of the incubation, the crystal violet assay [32] was performed. To 
do this, the planktonic culture was removed from the wells, which were washed three times with 
sterile PBS prior to staining with 0.04% crystal violet for 20 min. The colorant excess was 
eliminated by three successive washes with sterile PBS. Finally, the crystal violet was solubilized 
with 33% acetic acid and samples optical absorbance values were determined at 630 nm by using a 
microtiter plate reader (FLUOstar Omega, BMG LABTECH, Germany). To determine the 
percentage of viable bacterial cells inside the biofilm structure, upon biofilm disruption with 0,1% 
Triton X-100, bacterial cells were ten-fold diluted on solid TSA and incubated for 16 h at 37 °C. 
Once evaluated the number of colony forming units, bacterial cell survival was calculated as 
follows: (CFUin treated sample/CFUin untreated sample) x 100.  
 
2.4.7 Cytotoxicity Assay 
Cytotoxic effects of peptide on Raw 264.7 cells were determined using the cell 
proliferation reagent WST-1 (Roche Applied Science, Mannheim, Germany), designed to be used 
for the spectrophotometric quantification of cell proliferation. Briefly 5×10
4 
cells were seeded into a 
96-well plate and incubated at 37°C with 5% CO2. Medium was then replaced with 100 μl of fresh 
media containing peptide solution to a final concentration ranging from 0–40 μM/well. After 24 h 
of incubation at 37°C, the peptide-containing medium was removed, and 100 μl of fresh medium 
containing 10% WST-1 reagent was added to each well and incubated for 30 min at 37°C in the 
dark. Subsequently, the absorbance was measured in a microtiter plate reader (FLUOstar Omega, 
BMG labtech) at 450 nm, using 650 nm as the reference wavelength. 
 
2.4.8 Hemolytic Assay 
EDTA anti-coagulated mouse blood was centrifuged for 10 min at 800 × g (20 °C) to 
sediment the red blood cells. Pelleted RBCs were washed three times and diluted 200-fold in PBS. 
In 96-well polypropylene plates, 75 μl of serial peptide dilutions (0–80 μM) were mixed with an 
equal volume of RBC suspension and incubated for 1 h at 37 °C. PBS served as baseline and a 0.2% 
(v/v) Triton X-100 solution served as a control for complete lysis. Supernatants, collected after 10 
min centrifugation at 1300 × g (20 °C), were transferred into polystyrene 96-wells plates and 
absorbance was measured at 405 nm. Hemolysis (%) was calculated as follows: ((APeptide 
−ABlank)/(ATriton − ABlank)) × 100. 
 
2.4.9 Measurement of nitric oxide production  
Nitric oxide production was assessed as the accumulation of nitrite (NO2
−
) in cell 
supernatants as a result of 24 h incubation period. Nitrite concentrations were determined by a 
colorimetric reaction using the Griess reagent. Briefly, cell culture supernatants were mixed with an 
equal volume of 1% sulfanilamide (dissolved in 2.5% phosphoric acid) and incubated for 5 min. 
The same volume of 0.1% N-(1-naphthyl) ethylenediamine dihydrochloride was added and 
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incubated for 5 min. The absorbance was measured at 520 nm using a 96-well microplate reader 
(FLUOstar Omega, BMG labtech). 
 
2.4.10 Inhibition of IL-6 production mediated by GVF27 
The ability of the peptide to modulate cytokine production in RAW 264.7 cells was 
measured by ELISA (enzyme-linked immunosorbent assay). Cells (5×10
4 
cells) were seeded into 
96-wells microtiter plates. Next day culture medium was discarded and replaced with fresh medium 
containing peptide alone (5 or 20 M) for an initial incubation of 2h followed by addition of 50 
ng/mL LPS from Salmonella Minnesota or, alternatively, with 50 ng/mL LPS for an initial 
incubation of 2h followed by addition of peptide (5 or 20 M) or of a mixture of peptide (5 or 20 
M) and 50 ng/mL LPS. In all the cases, culture supernatants were collected after 24 h. After each 
pre-incubation, either with LPS or with peptide, and prior to the subsequent addition of peptide or 
LPS to murine macrophages, at least three washing steps were performed to remove any residual 
traces of agents previously used. Expression levels of mouse IL-6 were measured using the 
commercial available DuoSet ELISA kits (R&D Systems), following the protocols provided by the 
manufacturer. All samples were centrifuged briefly at 5,000 rpm for 3 min at room temperature to 
remove cell debris prior to use. Microtiter plates were read at 450 nm using 550 nm as a reference 
wavelength to correct optical imperfections of the microtiter plate.  
 
2.4.11 LPS binding assay 
The ability of GVF27 to neutralize LPS was determined using the commercially 
available Limulus amebocyte lysate (LAL) assay (Pierce® LAL Chromogenic Endotoxin 
Quantitation Kit, Thermo Scientific, USA). Briefly, 25 μl of serially diluted peptide (25,12.5, 6.25 
µM) was added to 25 μl of 0.5 U/ml E. coli O11:B4 LPS for 30 min at 37 °C, followed by 
incubation with 50 μl of amoebocyte lysate reagent for 10 min. Absorbance at 405 nm was 
measured 10 min after the addition of 100 μl of the chromogenic substrate, Ac-Ile-Glu-Ala-Arg-p-
nitroanilide. The amount of non-bound LPS was extrapolated from a standard curve, and percentage 
inhibition calculated as: [(amount of free LPS in control samples) − (amount of free LPS in test 
samples)]×100/amount of free LPS in control samples. 
 
2.4.12 Spectroscopic studies 
CD spectra of GVF27 were recorded with a J-810 spectropolarimeter equipped with a Peltier 
temperature control system (Model PTC- 423-S, Jasco Europe, Cremella, LC, Italy). Far-UV 
measurements (190–260 nm) were carried out at 20° C using a 0.1 cm optical path length cell and a 
peptide concentration of 25M. Baseline was corrected by subtracting the complete buffer 
spectrum. CD spectra were carried out in the presence of LPS from Pseudomonas aeruginosa strain 
10 (Sigma, purified by phenol extraction) and from P. aeruginosa clinical strain KK27 [29]. Further 
analyses were carried out in the presence of lipotechoic acid from Staphylococcus aureus (LTA, 
Product Number L 2515, Sigma). All measurements were recorded using different concentration of 
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each compound (from 0.05 to 1.0 mg/ml). Baseline was corrected by subtracting the spectrum of 
both LPS and LTA alone at the same concentration. Additional CD spectra were performed using 
different concentrations of trifluoroethanol (TFE) (0-40%). Deconvolutions of CD spectra were 
obtained using the web-based program CdPro (http://lamar.colostate.edu/~sreeram/CDPro/). 
Fluorescence experiments were carried out under the same conditions used for CD analyses. Fluorescence 
spectra were collected at 20°C using a Varian Cary Eclipse spectrophotometer at excitation of 295 and 280 
nm, a 1.0 cm path length cell at 5 em and 5 ex. Emission spectra (300-400 nm) were collected in the 
presence of 40% TFE, 5 mg/ml LPS or 10 mg/ml LTA. 
 
2.4.13 LPS micelles measurements by using dynamic light scattering (DLS) 
To estimate the average size of the LPS particles, the Hydrodynamic Radii (RH) was 
measured by Dynamic Light Scattering technique (DLS). DLS measurements were carried out 
using a Zetasizer Nano ZS (Malvern Instruments, Westborough, MA) equipped with a 173° 
backscatter detector, at 25 °C, using a disposable sizing cuvette. DLS measurements in triplicate 
were carried out on aqueous LPS and LTA samples at 0.5 mg/mL. Data were analyzed using the 
Software of OMNISIZE (Viscotek). LPS and LTA size measurements were performed before and 
after peptide addition (0.5 mg/ml). 
 
2.4.14 Nuclear magnetic resonance spectroscopy 
NMR experiments were recorded at 25 °C on a Varian Unity INOVA 600 MHz NMR 
spectrometer equipped with a cold probe. Two-dimensional (2D) nuclear Overhauser effect 
spectroscopy (NOESY), total correlation spectroscopy (TOCSY) and 2D double-quantum-filtered 
correlated spectroscopy (DQFCOSY) experiments were recorded. NOESY mixing times were 200 
ms and TOCSY mixing times were 70 ms. These experiments were collected with 512 and 1024 
complex points with acquisition times of 64 and 128 ms in the indirectly and directly acquired 1H 
dimensions, respectively. The DQFCOSY experiment was collected with 1024 and 2048 complex 
points and acquisition times of 128 and 256 ms in the indirectly and directly acquired 1H 
dimensions, respectively. In all experiments water suppression was obtained using pre-saturation in 
order to simultaneously suppress the hydroxyl protons from TFE that are in fast exchange with 
protons from water. Hydroxyl protons from TFE were seen to attenuate signals in both 1D and 2D 
datasets in WATERGATE based suppression. 1D spectra were analyzed using ACD/NMR 
Processor 12.0 (ACD/NMR Processor Freeware, Version 12.01 Advanced Chemistry Development, 
Inc., Toronto, ON, Canada (2012), www.acdlabs.com). 2D TOCSY and NOESY spectra for 1H 
chemical shift assignment were analyzed using Neasy, a tool available in CARA (Computer Aided 
Resonance Assignment) software (Keller, R. L. J. The Computer Aided Resonance Assignment 
Tutorial.  CANTINA Verlag, 2004, downloaded from cara.nmr.ch). Structure calculation was 
performed with the program CYANA version 2.1 [33]. The NOE cross peak intensities were used to 
obtain distance constraints. The angle restraints were derived from 3JHNHα coupling constants. 
Structure calculations were initiated from 100 random conformers; the 20 structures with the lowest 
CYANA target function ns were analyzed with the programs MOLMOL [34] and PyMOL 
Molecular Graphics System, Version 1.8 Schrödinger, LLC. (http://www.pymol.org/). 
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2.4.15 Intracellular bacterial killing assay 
2x10
5
 RAW 264.7 cells were incubated with 1-10 M at 37°C for 2h and then washed 
three times with sterile PBS. Cells were incubated with 1x10
8
 CFU/mL of Salmonella enterica 
Typhimurium ATCC 14028 at 37°C in DMEM supplemented with 10% FBS, 2 mM L-glutamine 
but without any antibiotics. After 1 h of infection, cells were washed three times with PBS to move 
away un-phagocyted bacteria. To ensure that extracellular environment was free from bacteria, cells 
were incubated 1h at 37°C with DMEM supplemented with 10% FBS, 2 mM L-glutamine and Pen-
Strep as source of antibiotics. Then, cells were washed three times with PBS again. Cells were lysed 
using 0.1% Triton X-100 in PBS for 5 minutes at room temperature to release intracellular bacteria. 
Thereafter, the lysates were serially diluted and plated onto agar plates. The following day, viable 
bacteria were counted (CFU). 
 
2.4.16 Statistics 
Results are presented as the mean ± standard error of the mean (SEM) of at least three 
independent experiments. Statistical significance was assessed with one-way ANOVA in Prism 
software, version 6.02 (GraphPad Prism, La Jolla, CA, USA).  All samples were compared to the 
negative control. *p < 0.05; **p < 0.01; ***p < 0.001. 
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Chapter 3 
 
Novel human bioactive peptides identified 
in Apolipoprotein B: Evaluation of their 
therapeutic potential. 
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3.1 Introduction 
 
Apolipoproteins are the main protein components of plasma lipoproteins and, 
intriguingly, a source of bioactive peptides. Reports have shown that peptides derived from the 
cationic receptor binding region of Apolipoprotein E (ApoE141-149) are endowed with broad anti-
infective activity [1]. Apolipoprotein B (ApoB) also contains two LDL (low-density lipoprotein) 
receptor binding domains, namely region A (ApoB3147-3157) and region B (ApoB3359-3367). 
Region B, more uniformly conserved across species and primarily involved in receptor binding, has 
been found to be endowed with a significant antiviral activity. Moreover, peptides derived from 
ApoB have been already used in vaccine preparations [2]. As mentioned in Chapter 1, recently, 
Pane K. et al. developed an in silico method [3] to identify HDPs in protein precursors and to 
predict quantitatively their antibacterial activity. This method allows the identification of novel 
HDPs within the sequence of known proteins (“cryptic” HDPs), as demonstrated by the 
identification of a novel cationic HDP endowed with antibacterial and immunomodulatory activities 
in human ApoE [4].  
Further, this method has been applied to the human Apolipoprotein B (ApoB) isoform, and 
two putative cryptic HDP have been predicted and named ApoBS and ApoBL. The sequence of 
peptide ApoBL is PHVALKPGKLKFIIPSPKRPVKLLSGGNTLHLVSTTKT, while that of peptide 
ApoBS is PHVALKPGKLKFIIPSPKRPVKLLSG. To evaluate the therapeutic potential of these 
peptides, we analysed their structure, antimicrobial and anti-biofilm activities, the ability to act in 
synergy with conventional antibiotics, their anti-inflammatory and wound healing properties, and 
their possible toxic effects on eukaryotic cells. 
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3.2 Results 
 
3.2.1 Antimicrobial activity of ApoBL and ApoBS peptides   
 
The antibacterial activity of ApoB derived peptides was determined by measuring their 
MIC100 values on a panel of Gram-negative and Gram-positive bacterial strains (Table 1). A 
significant antimicrobial activity of ApoBL and ApoBS peptides was detected towards four out of 
eight strains tested, i.e. E. coli ATCC 25922, P. aeruginosa PAO1, B. globigii TNO BM013, and B. 
licheniformis 21424, for which almost identical MIC100 values were calculated for both ApoB 
derived peptides. Notably, MIC100 values were found to be identical, or even significantly lower 
than those determined when cathelidin-2 (CATH-2) peptide, a known HDP from chicken [5], was 
tested as a positive control on the above mentioned strains.  
Hence, it can be concluded that ApoBL and ApoBS peptides are endowed with a broad-range 
antimicrobial activity, being effective on both Gram-negative and Gram-positive bacterial strains. 
On the other hand, ApoB derived peptides were found to be ineffective towards P. aeruginosa 
ATCC 27853, methicillin-resistant S. aureus (MRSA WKZ-2), and S. aureus 29213, while, in the 
case of S. enteriditis 706 RIVM, a significant antibacterial effect was exerted only by ApoBL 
peptide.    
 
 
 
Table 1. Minimum Inhibitory Concentration (MIC, µM) values determined for ApoB
L
 and ApoB
S
 peptides 
tested on a panel of Gram-positive and Gram-negative bacterial strains. Chicken CATH-2 peptide was used 
as a positive control. Values were obtained from a minimum of three independent experiments. 
 
 
3.2.2 Combination therapy analyses  
 
To potentiate the antimicrobial efficacy of ApoB derived peptides for therapeutic 
purposes, especially against P. aeruginosa and S. aureus strains, we carried out combination 
therapy analyses by concomitantly administrating peptides and antibiotics in different combinations 
to bacteria. One of the best known test to evaluate synergism between two compounds is the so 
called “chequerboard” experiment in which a two-dimensional array of serial concentrations of test 
compounds is used as the basis for calculation of a fractional inhibitory concentration (FIC) index 
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to demonstrate that paired combinations of agents can exert inhibitory effects that are more than the 
sum of their effects alone. It is generally accepted that FIC indexes ≤ 0.5 are indicative of 
“synergy”; FIC indexes comprised between > 0.5 and – 4.0 are, instead, associated to “additive” or 
“no interaction” effects, whereas FIC indexes > 4.0 are indicative of “antagonism” [6].   
As reported in Table 2, all the combinations tested were found to be effective, either with 
additive or synergistic effects between peptides and antibiotics. Notably, no FIC indexes higher 
than 2 were measured. The most potent combinations were obtained in the presence of EDTA, 
which was selected for its ability to affect bacterial outer membrane permeability, thus sensitizing 
bacteria to a number of antibiotics [7]. Very pronounced synergistic effects were observed for both 
ApoB derived peptides in combination with EDTA on S. aureus MRSA WKZ-2 and both P. 
aeuroginosa strains. We also found that both ApoBL and ApoBS showed synergism with the 
systemic antibiotic ciprofloxacin against all the strains tested. Similarly, we observed synergistic 
effects between both ApoB derived peptides and colistin against all the strains tested, except for S. 
aureus ATTC 29213. Synergistic effects were also observed in combination with vancomycin 
against S. aureus MRSA WKZ-2, P. aeruginosa strains and E. coli ATTC 25922. In the presence of 
erythromycin, synergistic effects were observed only against P. aeruginosa ATCC 27853, with a 
FIC index of 0.38 and 0.17 for ApoBL and ApoBS peptides, respectively.  
In the case of kanamycin, a different response was obtained depending on the peptide and the 
specific bacterial strain. In fact, ApoBL was found to act synergistically with this antibiotic 
prevalently on Gram-negative bacteria, particularly on the P. aeruginosa strains. ApoBS peptide, 
instead, was found to be very active against both S. aureus strains as well as against P. aeruginosa 
PAO1 strain (FIC indexes < 0.4).  
It should be emphasized that combinations of ApoB derived peptides with antibiotics and 
EDTA were found to have a strong antimicrobial activity also towards strains on which the peptides 
alone were found to be ineffective, such as both S. aureus strains and P. aeruginosa ATCC 27853 
(Table 2). Notably, we did not observe any antagonistic interactions between the peptides and the 
antimicrobials under test. 
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Table 2. Fractional inhibitory concentration (FIC) indexes determined for ApoB
L
 and ApoB
S
 peptides tested 
in combination with antibiotics or EDTA on Gram-positive and Gram-negative bacterial strains. Indexes 
were obtained from a minimum of three independent experiments, each one carried out with triplicate 
determinations. 
 
3.2.3 Anti-biofilm activity of ApoBL and ApoBS peptides   
 
Anti-biofilm peptides represent a very promising approach to treat biofilm-related 
infections and have an extraordinary ability to interfere with various stages of the biofilm growth 
mode [8]. To test whether ApoB derived peptides are endowed with anti-biofilm activity, we 
performed experiments on different bacterial strains, such as E. coli ATCC 25922, Pseudomonas 
aeruginosa PAO1, Pseudomonas aeruginosa ATCC 27853, and methicillin-resistant 
Staphylococcus aureus MRSA WKZ-2 in BM2 medium. As a control, the same experiments were 
performed using CATH-2 and LL-37 peptides. LL-37 is a human HDP known to have a significant 
anti-biofilm activity against multidrug-resistant bacterial strains [9].  
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At first, we evaluated the peptide effects on biofilm attachment. To do this, the bacterial 
culture, following over-night growth, was diluted in BM2 medium containing increasing 
concentrations of the peptide under test (0-1 μM), and incubated for 4 h at 37 ˚C. Following 
incubation, biofilm analysis by crystal violet staining revealed a significant dose-dependent 
inhibition of biofilm attachment in the case of E. coli ATCC 25922 (Fig. 1a) and S. aureus MRSA 
WKZ-2 (Fig. 1d) strains treated with ApoBL (continuous line in Fig. 1a, d) or ApoBS (smaller 
dashed line in Fig. 1a, d) peptides. Similar results were obtained on these two strains in the case of 
control peptides, such as CATH-2 (larger dashed line in Fig. 1a, d) and LL-37 (dotted line in Fig. 
1a, d). Strong effects were also exerted by ApoB derived peptides on biofilm attachment in the case 
of P. aeruginosa PAO1 strain. A less pronounced effect of ApoB derived peptides (about 20% 
inhibition) was observed, instead, on P. aeruginosa ATCC 27853 biofilm attachment.  
We also demonstrated that ApoB derived peptides have a strong effect on biofilm formation. 
To investigate this phenomenon, we followed the experimental procedure described above with the 
only exception that bacterial cells were incubated with increasing concentrations of peptides for 24 
h at 37 °C. Also in this case, we observed a significant dose-dependent inhibition of biofilm 
formation in the case of E. coli ATCC 25922 (Fig. 1b) and S. aureus MRSA WKZ-2 (Fig. 1e) 
strains treated with ApoBL (continuous line in Fig. 1b, e) or ApoBS (smaller dashed line in Fig. 1b, 
e) peptides. Similar effects on biofilm formation were also obtained in the case of control peptides 
CATH-2 (larger dashed line in Fig. 1b, e) and LL-37 (dotted line in Fig. 1b, e). ApoB derived 
peptides strongly affected also P. aeruginosa PAO1biofilm formation. In the case of P. aeruginosa 
ATCC 27853, instead, a less pronounced effect (about 20% biofilm formation inhibition) was 
observed for all the peptides under test.  
Even more interestingly, ApoB derived peptides were also found to strongly affect the 
preformed biofilm. In fact, by incubating E. coli ATCC 25922 (Fig. 1c) and S. aureus MRSA 
WKZ-2 (Fig. 1f) strains preformed biofilm with increasing concentrations of ApoBL (continuous 
line in Fig. 1c, f) or ApoBS (smaller dashed line in Fig. 1c, f) peptide, we found a significant 
inhibition (about 50%), even stronger than that observed in the case of CATH-2 control peptide 
(larger dashed line in Fig. 1c, f). Similar results were also observed in the case of P. aeruginosa 
PAO1 strain. When peptides were tested, instead, on P. aeruginosa ATCC 27853 preformed 
biofilm, a slight effect (about 20% inhibition) was observed for all the peptides except for CATH-2, 
which was found to exert a strong effect (about 50% inhibition,). We also evaluated the percentage 
of viable bacterial cells inside the biofilm structure by colony counting assay. We found that, even 
at the highest ApoB derived peptides concentrations tested, a significant portion of bacterial cells 
appeared to be still alive (continuous and smaller dashed lines in Fig. 2 and Table 3). Similar 
results were also observed in the case of LL-37 control peptide (dotted lines in Fig. 2). In the case 
of CATH-2 peptide, instead, a strong effect on cell viability was observed in the case of E. coli 
ATCC 25922 and S. aureus MRSA WKZ-2 strains (larger dashed lines in Fig. 2).  
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Figure 1. Anti-biofilm activity of ApoBL (‒), ApoBS (- - -), CATH-2 (‒ ‒ ‒), and LL-37 (•••) peptides on E. 
coli ATCC 25922 (a, b, c) and S. aureus MRSA WKZ-2 (d, e, f) strains in BM2 medium. The effects of 
increasing concentrations of peptides were evaluated either on biofilm attachment (a, d), biofilm formation 
(b, e), or on pre-formed (c, f) biofilm. Biofilm was stained with crystal violet and measured at 630 nm. Data 
represent the mean (± standard deviation, SD) of at least three independent experiments, each one carried out 
with triplicate determinations.    
 
 
 
Figure 2. Effects of increasing concentrations of ApoBL (‒), ApoBS (- - -), CATH-2 (‒ ‒ ‒), and LL-37 (•••) 
peptides on the viability of E. coli ATCC 25922 (a, b, c) and S. aureus MRSA WKZ-2 (d, e, f) cells inside 
the biofilm structure. Cell viability was assessed by colony counting assay, and expressed as the percentage 
of viable bacterial cells in treated samples with respect to the control untreated sample. Data represent the 
mean (± standard deviation, SD) of at least three independent experiments, each one carried out with 
triplicate determinations. 
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Table 3. Effect of ApoB
L
, ApoB
S
, CATH-2, and LL-37 peptides (1 µM) on biofilm attachment, formation, 
and eradication. To determine the percentage of viable bacterial cells inside the biofilm structure, biofilm 
was lysed with Triton X-100 (0,1%), bacterial cells were ten-fold diluted, and colonies were counted after an 
incubation of 16 h at 37 °C. Data are expressed as percentage with respect to control untreated samples, and 
represent the mean (± standard deviation, SD) of at least three independent experiments, each one carried out 
with triplicate determinations. 
 
 
3.2.4 Biocompatibility of ApoBL and ApoBS peptides  
 
The development of HDPs as therapeutic agents is strictly related to their selective 
toxicity towards bacterial cells [10]. The presence of zwitterionic phospholipids and cholesterol on 
the outer leaflet of eukaryotic cell membranes largely accounts for the preference of HDPs for 
bacterial membranes over eukaryotic membranes [11].  
To deepen on the therapeutic potential of ApoB derived peptides, we analysed their 
cytotoxic effects towards a panel of mouse and human eukaryotic cells. The addition of increasing 
concentrations (from 0.625 to 20 μM) of ApoB derived peptides to mouse macrophages Raw 264.7 
cells for 24 h did not result in any significant reduction in cell viability (Fig. 3a and b). A slight 
toxicity was detected only at the highest peptide concentrations tested (10 and 20 μM). Moreover, 
no significant toxic effects were detected when ApoB derived peptides were assayed on human 
cervical cancer HeLa cells (data not shown), while a slight toxicity (~20%) was observed in the 
case of human keratinocytes (HaCaT cells) at the highest peptide concentration tested (20 μM). 
ApoB derived peptides were also tested on murine red blood cells (RBCs) to exclude hemolytic 
affects. As shown in Fig. 4, both peptides did not exert any lytic effect on mouse RBCs, even at the 
highest concentration tested (20 μM). It should also be underlined that the antibacterial activity of 
ApoB derived peptides was detected at peptide concentrations comparable (Table 1) to those used 
in the cytotoxicity assays described above. 
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Figure 3. Effects of ApoBL (a) and ApoBS (b) peptides on the viability of RAW 264.7 cells. Cell viability 
was assessed by WST-1 assay, and expressed as the percentage of viable cells with respect to controls 
(untreated cells). Error bars indicate standard deviations obtained from at least three independent 
experiments, each one carried out with triplicate determinations.  
 
 
 
Figure 4. Hemolytic activity of ApoBL (a) and ApoBS (b) peptides towards murine red blood cells (RBCs) 
after 1 h of incubation at 37 °C. Data represent the mean (± standard deviation, SD) of at least three 
independent experiments, each one carried out with triplicate determinations. 
 
 
3.2.5 Analysis of the immunomodulatory activity of ApoBL and ApoBS peptides 
 
Since it is widely reported that HDPs are able to mitigate the pro-inflammatory effects 
induced by endotoxins [12], such as LPS, we tested the anti-inflammatory properties of ApoB 
derived peptides by monitoring their effects on LPS induced interleukin-6 (IL-6), as well as on 
nitric oxide (NO) release in murine macrophages (RAW 264.7 cell line). In fact, it is known that, 
upon activation by internal and external stimuli, macrophages produce and secrete various 
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endogenous inflammatory mediators, such as nitric oxide (NO) and pro-inflammatory cytokines, 
including interleukin-6 [13]. An excess of NO, produced by inducible nitric oxide synthase (iNOS) 
during inflammation, activates the synthesis of inflammatory mediators, which can in turn cause 
tissue damage, genetic mutations, and nerve injury [14]. 
To test the effects of ApoB derived peptides on the release of IL-6, ELISA assays were 
performed on LPS stimulated RAW 264.7 cells. As shown in Fig. 5a and b, a significant release of 
IL-6 was observed in control cells incubated with LPS from Salmonella Minnesota (50 ng/mL). 
When murine macrophages were incubated with LPS (50 ng/mL) in the presence of either ApoBL 
(Fig. 5a) or ApoBS (Fig. 5b) peptides, at 5 and 20 µM peptide concentration, a strong decrease of 
IL-6 release was observed with respect to control cells stimulated with LPS in the absence of 
peptides. Moreover, we found that peptides have a significant protective effect on LPS stimulated 
RAW 264.7 cells. In fact, when macrophages were pre-treated for 2 h with either ApoBL or ApoBS 
peptide and then incubated for further 24 h with LPS, a significant decrease of IL-6 release was 
observed (Fig. 5a and b). Similar results were observed when the effects of peptides were tested on 
NO release (Fig. 5c and d). Also in this case, following co-incubation of cells with LPS from 
Salmonella Minnesota and either ApoBL or ApoBS peptide, a significant attenuation of NO release 
with respect to control cells was detected (Fig. 5c and d). However, in this case, it has to be noticed 
that a significant effect of peptides on NO release was observed only at the highest peptide 
concentration tested (20 µM), while at 5 µM concentration both peptides were found to be almost 
ineffective (Fig. 5c and d). However, when RAW 264.7 cells were pre-treated for two h with 5 or 
20 µM of ApoBL or ApoBS peptides and subsequently stimulated for 24 h with LPS (50 ng/mL), a 
significant reduction of NO release was observed even at 5 µM peptide concentration (Fig. 5c and 
d), thus confirming a significant protective effect of both peptides on LPS stimulated RAW 264.7 
cells. 
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Figure 5. Effects of ApoB derived peptides on the release of IL-6 (a, b) and NO (c, d) in mouse 
macrophages RAW 264.7 stimulated with LPS (50 ng/mL) from Salmonella Minnesota. The effects of 
ApoBL (a, c) and ApoBS (b, d) peptides were evaluated either co-incubating cells with peptides (5 or 20 µM) 
and LPS (oblique grey lanes) or by treating cells with peptides (5 or 20 µM) for 2 h at 37 °C prior to 
incubation with LPS (chessboard bars). Results were compared to those obtained in the case of control 
untreated cells (white bars), cells stimulated with the LPS alone (black bars), or cells incubated with two 
different concentrations (5 or 20 µM) of peptide (grey bars). Data represent the mean (± standard deviation, 
SD) of at least three independent experiments, each one carried out with triplicate determinations.   
 
 
3.2.6 Wound healing activity of ApoBL peptide 
 
Numerous studies support the hypothesis that human HDPs promote wound healing in 
skin, by modulating cytokine production, cell migration, proliferation and, in some cases, 
angiogenesis [15]. Based on this, we performed experiments to evaluate if ApoBL peptide is able to 
stimulate “wound” re-epithelialization by human keratinocytes (HaCaT cell line). To this purpose, 
we performed a classical wound healing assay to evaluate peptide effects on cell migration. Hence, 
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HaCaT cell monolayers were pre-treated with 3 µM mitomycin C for 30 minutes, in order to inhibit 
cell proliferation, and then wounded with a pipette tip to remove cells from a specific region of the 
monolayer. Cells were then washed with PBS and incubated with increasing concentrations of 
ApoBL (0.5, 10, and 20 µM). It is well known that the spreading of cells in the wound area is due to 
two mechanisms, i.e. cell motility and cell proliferation [16]. Pre-treatment with mitomycin C 
allowed us to exclude any influence of cell proliferation on the wound healing process. In Fig. 6a, 
we reported the images acquired during a wound healing experiment for control cells, and cells 
treated with 20 µM ApoBL peptide at three time points, i.e. t=0 h, t=3 h after the lag time (tL), and 
t=5 h the after tL. By comparing the images obtained for each time point, the cells treated with 20 
µM peptide appear to close the wound faster than the control cells.  
In order to quantify the wound closure, we used an automated image analysis software, that 
allowed us to measure the size of the cell-free area (A) for each time point. Obtained values were 
normalized with respect to the value measured at time 0 (A0) for each field of view, and plotted as a 
function of time (Fig. 6b). In Fig. 6a, A/A0 values were found to be 0.20, and 0.07 for the control 
sample, and for the cells treated with 20 µM peptide, respectively, at t=5 h after tL. This evidence 
further confirms the ability of 20 µM ApoBL peptide to significantly stimulate wound re-
epithelialization by human keratinocytes.  As an example, we reported in Fig. 6b A/A0 values, 
obtained in the case of a control sample, as a function of time. It emerges that, after an initial lag 
phase, the wound area decreases with a constant velocity. The initial lag phase, corresponding to a 
transient time period (tL) before the linear decrease of the wound area, has been observed for all the 
analysed samples, and has been found to range between 3 and 5 h independently from peptide 
concentrations under test (Fig. 6c).  
Following the lag phase, A/A0 values were always found to linearly decrease over time. The 
slope (α) of the line represents the measure of the “wound” closure velocity. For each sample, this 
value (α) was normalized with respect to the value obtained in the case of the control sample (αcontr), 
and plotted as a function of peptide concentration (Fig. 6d). It appears that the cells treated with the 
peptide are characterized by an increase in the “wound” closure velocity with respect to the control 
cells (α/αcontr>1).  
Overall, our results indicate that ApoBL peptide is able to promote the migration and the 
consequent wound healing in HaCaT keratinocyte monolayers when tested at concentration values 
ranging between 0.5 and 20 µM.   
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Figure 6: Wound healing activity of ApoBL peptide on HaCaT cells monolayer. Cells were pre-treated for 
30 min with 3 µM mitomycin C, and then wounded prior to incubation with ApoBL peptide (10 – 20 µM) for 
12 h at 37 °C. Images were acquired for untreated HaCaT cells and for cells treated with 20 µM peptide (a). 
The lag phase time (tL) corresponds to the time interval before the linear decrease of the wound area. Images 
were acquired at time t=0 (a, on the left), 3 h after tL (a, in the middle) and 5 h after tL (a, on the right). For 
each sample, A/A0 values are reported, where A is the wound area after a specific incubation time and A0 is 
the wound area at time 0. Scale bar = 150 μm. In b, evolution in time of the wound area (A), normalized with 
respect to A0, is reported for a control sample. A homemade automated image analysis software was used to 
measure the size of the cell-free area (A) for each time point. For A/A0 values <0.8, a linear correlation with 
the incubation time was found. The slope -α of the linear fit, reported as a continuous line, represents a 
measure of the wound closure velocity. In c, determined tL values are reported as a function of peptide 
concentration (0.5 - 10 - 20 µM). In d, wound closure velocity (α), normalized with respect to control sample 
(αcontr), is reported as a function of peptide concentration (0.5 - 10 - 20 µM). The dashed line corresponds to 
α/αcontr =1. In c and d, each data point represents the mean (± standard error) of three independent 
experiments.  
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3.3 Conclusions 
 
Here, we focused our attention on the two identified ApoB derived HDPs, here named 
ApoBL and ApoBS, 38- and 26-residue long, respectively. Both peptides were found to exhibit 
antibacterial activities against both Gram-positive and Gram-negative strains, including the 
pathogenic strains P. aeruginosa PAO1 and B. globigii TNO BM013, while having negligible 
cytotoxic effects on a panel of human and murine cell lines. It has to be underlined that ApoB 
derived peptides were found to be ineffective towards P. aeruginosa ATCC 27853, methicillin-
resistant S. aureus (MRSA WKZ-2), and S. aureus ATTC 29213 strains, while, in the case of S. 
enteriditis 706 RIVM strain, a significant antibacterial effect was exerted only by ApoBL peptide. 
This observation is in agreement with previous findings indicating that most natural cationic HDPs 
do not appear to be highly optimized for direct antimicrobial activity, since it is likely that multiple 
modestly active peptides with concomitant immunomodulatory activities work effectively in 
combination and/or when induced or delivered to sites of infection [17]. 
Indeed, considering this, we performed combination therapy analyses and found that both 
ApoB derived peptides are able to synergistically act with either commonly used antibiotics or 
EDTA, which was selected for its ability to affect bacterial outer membrane permeability, thus 
sensitizing bacteria to a number of antibiotics [18]. Intriguingly, this application allows the 
reduction of therapeutic doses with a consequent mitigation of toxic effects, and possibility to target 
a broad spectrum of pathogens. In addition, certain combination therapies have prevented the 
development of drug-resistance in bacteria. A membranolytic action of HDP is expected to produce 
synergetic effects when administered in combination with conventional antibiotics, and several 
studies have reported such findings. Cirioni et al. [19] compared the synergies of magainin II and 
cecropin A administered with or without rifampicin against MDR Pseudomonas aeruginosa strains 
both in vivo and in vitro and found significant reductions in bacterial multiplication, LPS and TNF-
α secretion in plasma and mortality. This finding suggested that the membrane-permeabilizing 
activity of peptides allows rifampicin to gain access to its intracellular target.  
In this work, when combined with conventional antibiotics or EDTA, both ApoB derived 
peptides showed synergist activity towards most of the strains under test, including methicillin-
resistant S. aureus MRSA WKZ-2 on which peptides alone were found to be ineffective even at 
high concentrations (40 µM). Interestingly, both ApoBL and ApoBS peptides showed synergism 
with systemic antibiotic ciprofloxacin against all the strains under test (FIC indexes ranging from 
0.3 to 0.44). ApoB derived peptides also showed synergistic effects with colistin against all the 
strains under test, except for S. aureus ATTC 29213, and with vancomycin against S. aureus MRSA 
WKZ-2, both P. aeruginosa strains and E. coli ATTC 25922 (FIC indexes ranging from 0.14 to 
0.5). Since both colistin and vancomycin are responsible for toxic effects at high concentrations 
[20], the possibility to use combination therapeutic approaches based on a reduced frequency of 
antibiotic administration and/or exposure to antibiotic may offer several advantages over 
conventional dosing schemes, as adverse side effects might be reduced.  
However, the most potent synergism was observed for both ApoB derived peptides in 
combination with EDTA, with FIC indexes ranging from 0.089 to 0.4. It should be highlighted that, 
although in some cases FIC indexes very close to 0.5 make difficult to discriminate between 
synergistic and additive effects, no antagonistic interactions were observed between the peptides 
and the antimicrobials under test. Furthermore, combinations of ApoB derived peptides with 
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antibiotics and EDTA were found to have a strong antimicrobial activity also towards strains on 
which the peptides alone were found to be ineffective, such as both S. aureus strains and P. 
aeruginosa ATCC 27853, indicating that in drug combinations a reciprocal facilitation and 
potentiation of different mechanisms of action is realized. 
Interestingly, ApoB derived peptides are also endowed with anti-biofilm activity. 
Microorganisms growing in a biofilm state are very resilient to the treatment by many antimicrobial 
agents. Indeed, biofilm infections are a significant problem in chronic and long-term infections, 
including those colonizing medical devices and implants [21]. Specific cationic HDPs have recently 
been described to possess multispecies anti-biofilm activity, which is independent of their activity 
against planktonic bacteria. ApoB derived peptides were found to be effective on biofilm formation, 
biofilm attachment, and were also found to strongly affect pre-formed biofilm. Interestingly, ApoB 
derived peptides anti-biofilm activity was detected even on bacterial strains not sensitive to peptide 
direct antimicrobial activity, such as S. aureus MRSA WKZ-2. 
Moreover, it has to be highlighted that both ApoBL and ApoBS peptides were found exert 
immunomodulatory activities by significantly decreasing the release of pro-inflammatory IL-6 and 
NO in murine RAW 264.7 macrophages under LPS stimulation. Both ApoB derived peptides were 
found to efficiently act either when the cells were co-incubated with the peptide under test in the 
presence of LPS or when the cells were pre-treated with the peptide for 2 h and then incubated with 
LPS for further 24 h, thus indicating that both peptides were able to exert significant protective 
effects. However, it has to be noticed that, differently from ApoBL peptide, ApoBS was found to 
play anti-inflammatory activities, when co-incubated with LPS, only at the highest peptide 
concentration tested (20 µM), whereas both ApoBS concentrations under test (5 and 20 µM) were 
found to efficiently exert a protective effect. This might be due to the fact that ApoB derived 
peptides probably exert their immunomodulatory activity through different mechanisms, with 
ApoBL peptide mainly acting by binding to LPS and consequently interfering with its activity on 
target cells, and ApoBS peptide mainly acting on cell membrane and competing with LPS for the 
binding to specific cell sites. All these observations associated to their multifunctional properties 
open interesting perspectives to their therapeutic applications. 
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3.4 Experimental procedures 
3.4.1. Bacterial strains and growth conditions  
Eight bacterial strains were used in the present study, i.e. E. coli ATCC 25922, 
methicillin-resistant Staphylococcus aureus (MRSA WKZ-2), Salmonella enteriditis 706 RIVM, 
Bacillus globigii TNO BM013, Bacillus licheniformis ATTC 21424, Staphylococcus aureus 
ATTC 29213, Pseudomonas aeruginosa ATCC 27853, and Pseudomonas aeruginosa PAO1. All 
bacterial strains were grown in Muller Hinton Broth (MHB, Becton Dickinson Difco, Franklin 
Lakes, NJ) and on Tryptic Soy Agar (TSA; Oxoid Ltd., Hampshire, UK). In all the experiments, 
bacteria were inoculated and grown overnight in MHB at 37 °C. The next day, bacteria were 
transferred to a fresh MHB tube and grown to mid-logarithmic phase. 
 
3.4.2. Synthetic peptides 
CATH-2 peptide was obtained from CPC Scientific Inc. (Sunnyvale, USA), and LL-37 
peptide was from Sigma Aldrich, Milan, Italy. 
  
3.4.3. Measurement of IL-6 release 
IL-6 levels were determined by ELISA assay (DuoSet ELISA kits, R&D Systems, 
Minneapolis, MN) following the manufacturer’s instructions. Briefly, RAW 264.7 cells (5×104) 
were seeded into 96-well microtiter plates, and grown to semi-confluency. After 24 h, the culture 
medium was replaced with fresh medium containing the peptides under test (5 or 20 µM) in the 
presence or in the absence of LPS from Salmonella Minnesota (50 ng/mL, Sigma Aldrich, Milan, 
Italy) for 24 h at 37 °C. When the protective effect of peptides was evaluated, cells were pre-
incubated with the peptides under test (5 or 20 µM) for 2 h at 37 °C. Following treatment, cells 
were washed three times with PBS prior to incubation with LPS (50 ng/mL) for further 24 h at 37 
°C. In each case, at the end of incubation, the culture supernatants were collected, and centrifuged 
at 5,000 rpm for 3 min at room temperature, in order to remove cell debris. Samples were then 
analysed by reading absorbance values at 450 nm using 550 nm as a reference wavelength at an 
automatic plate reader (FLUOstar Omega, BMG LABTECH, Ortenberg, Germany).  
 
3.4.4. Determination of NO production 
To determine the levels of NO released by RAW 264.7 cells, a colorimetric  assay based 
on the use of Griess  reagent (Sigma Aldrich, Milan, Italy) was performed. The levels of nitrite 
(NO
2−
) in cell supernatants were determined on the basis of a reference curve obtained by testing 
increasing amounts (from 1 to 50 μM) of sodium nitrite dissolved in water. Briefly, cell culture 
supernatants were mixed with equal volumes of 1% sulphanilamide dissolved in 2.5% phosphoric 
acid, and incubated for 5 min at room temperature. Samples were then diluted 1:1 (v/v) with 0.1% 
N-(1-naphthyl) ethylenediamine dihydrochloride, and incubated for further 5 min at room 
temperature. Absorbance values were then determined at 520 nm using an automatic plate reader 
(FLUOstar Omega, BMG LABTECH, Ortenberg, Germany). 
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3.4.5. Antimicrobial activity assay 
The antimicrobial activity of ApoB derived peptides was tested towards eight bacterial 
strains, i.e. E. coli ATCC 25922, methicillin-resistant Staphylococcus aureus (MRSA WKZ-2), 
Salmonella enteriditis 706 RIVM, Bacillus globigii TNO BM013, Bacillus licheniformis ATCC 
21424, Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853, and 
Pseudomonas aeruginosa PAO1. In each case, bacteria were grown to mid-logarithmic phase in 
MHB at 37 °C. Cells were then diluted to 2x10
6
 CFU/mL in Nutrient Broth (Difco, Becton 
Dickinson, Franklin Lakes, NJ) containing increasing amounts of either ApoBL or ApoBS peptide 
(0,6-40 µM). In order to add the same volume of peptide to each sample, starting from a peptide 
stock solution, two-fold serial dilutions were sequentially carried out, accordingly to broth 
microdilution method [22]. Following over-night incubation, MIC100 values were determined as 
the lowest peptide concentration responsible for no visible bacterial growth. 
 
3.4.6. Synergy evaluation 
Synergism between ApoB derived peptides and antimicrobial agents was assessed by 
the so called “checkerboard” assay against S. aureus MRSA WKZ-2, E. coli ATCC 25922, P. 
aeruginosa ATCC 27853, P. aeruginosa PAO1, and S. aureus ATCC 29213. To this purpose, 
ApoB derived peptides were tested in combination with EDTA or antibiotics, such as 
ciprofloxacin, colistin, erythromycin, kanamycin sulfate, and vancomycin. All these antimicrobial 
agents were from Sigma Aldrich, Milan, Italy. Two-fold serial dilutions of each ApoB derived 
peptide and each antimicrobial agent were tested in combination on each strain tested. To do this, 
we tested peptide concentrations ranging from 0 to 20 μM. In the case of antibiotics and EDTA, 
experiments were preliminarily performed to define for each compound the appropriate 
concentrations to use depending on the specific bacterial strain under test. Compound 
concentrations tested on each strain are reported in Table 4. The fractional inhibitory 
concentration (FIC) index was calculated as follows: FICA + FICB, where FICA = MIC of drug A 
in combination/MIC of drug A alone, and FICB = MIC of drug B in combination/MIC of drug B 
alone. FIC indexes ≤ 0.5 were classified as synergism, whereas FIC indexes between 0.5 and 4 
were associated to additive or “no interaction” effects [23]. Antagonism is usually associated to a 
FIC index > 4.  
 
Table 4. Range of antimicrobial agents concentrations tested for combination therapy analyses. Based on 
specific bacterial strain susceptibility, different concentrations of each compound were used in combination 
with ApoB derived peptides (0- 20 μM) to evaluate synergistic effects. 
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3.4.7. Anti-biofilm activity  
Anti-biofilm activity of ApoB derived peptides was tested on S. aureus MRSA WKZ-2, 
E. coli ATCC 25922, P. aeruginosa ATCC 27853, and P. aeruginosa PAO1 strains. Bacteria were 
grown over-night in MHB (Becton Dickinson Difco, Franklin Lakes, NJ), and then diluted to 
1×10
8
 CFU/mL in BM2 medium [24] containing increasing peptide concentrations (0 - 1 µM). 
Incubations with the peptides under test were carried out either for 4 h, in order to test peptide 
effects on biofilm attachment, or for 24 h, in order to test peptide effects on biofilm formation. 
When peptide effects on preformed biofilm were evaluated, bacterial cells were incubated for 24 h 
at 37 ˚C, and then treated with increasing concentrations (0 - 1 µM) of the peptides under test. In 
all the cases, at the end of the incubation, the crystal violet assay was performed. Samples optical 
absorbance values were determined at 630 nm by using a microtiter plate reader (FLUOstar 
Omega, BMG LABTECH, Germany). To determine the percentage of viable bacterial cells inside 
the biofilm structure, upon biofilm disruption with 0,1% Triton X-100 (Sigma Aldrich, Milan, 
Italy), bacterial cells were ten-fold diluted on solid TSA and incubated for 16 h at 37 °C. Once 
evaluated the number of colony forming units, bacterial cell survival was calculated as follows: 
(CFUin treated sample/CFUin untreated sample) ×100. 
 
3.4.8. Cytotoxicity assays 
Cytotoxic effects of ApoB derived peptides on RAW 264.7 cells were determined by 
using the cell proliferator reagent WST-1(Roche Applied Science, Mannheim, Germany). To this 
purpose, RAW 264.7 cells were plated into 96-well plates at a density of 5×10
4
 cells in 100 µL 
medium per well, and incubated over-night at 37 °C. Afterwards, cells were treated with 
increasing concentrations (0 - 20 μM) of the peptides under test for 24 h at 37 °C. Following 
incubation, peptide-containing medium was removed, and 100 μL of fresh medium containing 
10% WST-1 reagent was added to each well. Following an incubation of 30 min at 37 °C in the 
dark, sample absorbance values were measured at 450 nm using 650 nm as a reference wavelength 
at a microtiter plate reader (FLUOstar Omega, BMG LABTECH, Germany).  
 
3.4.9. Haemolytic activity 
The release of haemoglobin from mouse erythrocytes was used as a measure for the 
haemolytic activity of ApoB derived peptides. To do this, EDTA anti-coagulated mouse blood 
was centrifuged for 10 min at 800 x g at 20 °C, in order to obtain red blood cells (RBCs), which 
were washed three times, and 200-fold diluted in PBS. Subsequently, 75 µL aliquots of RBCs 
were added to 75 µL peptide solutions (final concentration ranging from 0 to 20 µM) in 96-well 
microtiter plates, and the mixture was incubated for 1 h at 37 ◦C. Following the incubation, the 
plate was centrifuged for 10 min at 1,300 × g at 20 °C, and 100 µL supernatant of each well were 
transferred to a new 96-well plate. Absorbance values were determined at 405 nm by using an 
automatic plate reader (FLUOstar Omega, BMG LABTECH, Germany), and the percentage of 
haemolysis was calculated by comparison with the control samples containing no peptide 
(negative control) or 0.2% (v/v) Triton X-100 (positive control, complete lysis). Haemolysis (%) = 
63 
 
[(Abs405 nm peptide − Abs405 nm negative control)/( Abs405 nm 0,2% Triton − Abs405 nm negative 
control)] × 100. 
 
3.4.10. Wound healing assay 
Wound heling activity of ApoBL peptide was evaluated as previously described [25]. 
Human HaCaT keratinocytes were seeded into 12-well plates at a density of 6.3 x 10
5
 cells/well in 
1 mL medium per well. Following an incubation of 24 h at 37°C, cells were pre-treated with 3 µM 
mitomycin C for 30 minutes, in order to inhibit cell proliferation [26]. Cell monolayers were then 
wounded with a pipette tip to remove cells from a specific region of the monolayer. The culture 
medium was then removed and the cells were washed twice with PBS. Cells were then incubated 
with fresh culture medium containing increasing concentrations of ApoBL peptide (0 – 0.5 – 10 – 
20 µM). Wound closure was then followed by multiple field time-lapse microscopy (TLM) 
experiments, using an inverted microscope (Zeiss Axiovert 200, Carl Zeiss, Germany) equipped 
with an incubator to control temperature, humidity and CO2 percentage. Images were iteratively 
acquired in phase contrast with a CCD video camera (Hamamatsu Orca AG, Japan) by using a 10x 
objective. The microscope was also equipped with a motorized stage and focus control 
(Marzhauser, Germany) enabling automated positioning of the acquired samples. The workstation 
was controlled through a homemade software in Labview. Each cell sample was analysed in 
duplicate, and in any case at least two fields of view were selected. Since three independents 
experiments were carried out, from 4 to 12 independent fields of view were analysed for each 
sample. The delay between consecutive imaging of the same field of view was set to 15 min. The 
wound closure dynamics were quantified by using a homemade automated image analysis 
software, that allowed to measure the size of the wound area for each time point (A). For each 
field of view, determined values were normalized respect to the value of the wound area at time 0 
(A0), and plotted as function of time. After an initial lag phase, the wound area was found to 
decrease with a constant velocity [27]. By reporting A/A0 values as a function of time, a linear 
decrease was observed for A/A0 values lower than 0.8. For each sample, the lag time tL was 
calculated as the time required to obtain an initial wound closure corresponding to A/A0=0.8. 
Being R
2
 typically higher than 0.98, the linear range of the curve was fitted, and the slope (-α) was 
considered a measure of the wound closure velocity. The values of wound closure velocity 
obtained for each field of view from three independent experiments were averaged (α), and 
normalized with respect to the value of the corresponding control sample (αcontr). For each peptide 
concentration tested, α/αcontr values obtained from three independent experiments were averaged 
and the standard error of the mean was calculated to account for reproducibility.  
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Chapter 4 
 
Novel bioactive peptides from PD-L1/2, a type 1 ribosome 
inactivating protein from Phytolacca dioica L.  
Broad evaluation of their antimicrobial properties and 
antibiofilm activities 
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4.1 Introduction 
 
Higher plants are sedentary and lack the adaptive immune system that many animals 
deploy when challenged by microbial pathogens. Nevertheless, plants are not defenseless, and have 
developed a variety of mechanisms to protect themselves against microbial attack.  
These include the production of proteins, secondary metabolites and reactive oxygen species that 
can inhibit the growth of microbial pathogens, the establishment of structural barriers such as lignin 
and polysaccharides that prevent penetration and colonization, and hypersensitivity responses that 
result in programmed cell death and isolate invading pathogens from sources of nutrients. Plants 
represent an extremely abundant and largely unexplored source of HDPs. The recent development 
of powerful high-throughput genomic techniques has disclosed the presence of large numbers, often 
even several hundreds of HDP-like genes in various plant genomes [1] indicating the importance of 
HDPs in the eukaryotes and particularly in plants. 
The innate immune system is a generic defense response of both animals and plants to fend off 
invading microbes. In plants, it does not show the same degree of specificity as the adaptive 
immunity of vertebrates that evolves a highly specific response after initial exposure to a challenge, 
but, as well as in animals, innate immunity is triggered after recognition of conserved microbe-
associated molecular patterns (MAMPs) by pattern recognition receptors. 
HDPs can occur in all plant organs. In unstressed organs, HDPs are usually most abundant in the 
outer cell layer lining the organ, which is consistent with a role for the HDPs in constitutive host 
defense against microbial invaders attacking from the outside.  
To note, as abundantly demonstrated, HDPs have the potential for use as anti-biofilm 
agents due to their different mechanisms, which include membrane-disrupting action, functional 
inhibition of proteins, binding with DNA, and detoxification of polysaccharides (lipopolysaccharide 
and lipoteichoic acid) and inhibiting molecules involved in biofilm formation induced via quorum 
sensing. Biofilms provide a survival advantage over planktonic or free-floating bacteria by 
enhancing nutrient trapping and colonization. Currently, biofilms are a widespread problem in 
hospitals and healthcare facilities. Indeed, the United States National Institutes of Health found that 
80% of chronic infections are related to biofilms. Moreover, many studies have found that biofilms 
are associated with dental plaque, endocarditis, lung infection, and infection through medical 
devices. Bacterial cells are embedded into a matrix of extracellular polymeric substance, which is 
composed of extracellular DNA, proteins, lipids, and polysaccharides with various configurations. 
These components are very important targets for overcoming both biofilms and drug-resistant 
bacteria.  
Specific databases with increasingly accessible information [2, 3] indicate that a number 
of HDPs were identified in proteins, known as HDP releasing proteins, not necessarily playing host 
defence activities. These proteins would release biologically active peptides upon proteolytic 
cleavage by bacterial and/or host proteases [4, 5]. A few of these bioactive peptides were found in 
cationic proteins (with an isoelectric point > 8.0), such as lysozyme [6], RNase A [7], histone H2A 
[8] and lactoferrin [9], all with high propensity to release unfolded peptides with a positive net 
charge.  
 In this framework, our research group identified, at first, an HDP in cationic PD-L4 enzyme, 
a type 1 ribosome inactivating protein (RIP) [10] from Phytolacca dioica L. [11], by a CNBr 
fragmentation approach performed on the native protein. RIPs are enzymes (3.2.2.22) identified in 
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plants, fungi, algae, and bacteria. They are endowed with N-glycosilase activity, which leads to the 
cleavage of a specific adenine residue at a conserved site of the 28S rRNA, with a consequent 
inhibition of protein synthesis [12]. They are classified as type 1 or 2 according to their structure. 
Type 1 RIPs are single-chain proteins, with a size of approximately 30 kDa and a basic pI, whereas 
dimeric type 2 RIPs consist of two peptide chains: an A chain of about 30 kDa, endowed with 
enzymatic activity, linked to a B chain of about 35 kDa, endowed with lectin activity and capable of 
binding to oligosaccharides containing galactose moieties [13]. Although the biological role of RIPs 
has not been completely elucidated, some reports indicate that they may be involved in host defence 
activities [14, 15].  
 To date, reports on HDPs derived from Phytolacca dioica L. are limited to our recent study 
[16] demonstrating that the identified peptide, named PDL440-65 exhibits structural and biological 
properties typical of host defence peptides. 
In order to evaluate the presence of novel bioactive peptides in further RIP members, such 
as PD-L1/2, dioicin1 and dioicin2 [17, 18], here we used the previously described bioinformatics 
approach, in order to identify potential cryptic HDPs in protein precursors and to predict their strain 
specific antibacterial activity [19]. As a result of this screening, two very promising HDPs have 
been identified in the N-terminal region of PD-L1/2 (amino acid position Ile50-Ser80, Fig. 1) [20], 
which were here named IKY23 and IKY31. The present chapter focuses on the characterization of 
the antibacterial and anti-biofilm activities of these two novel PD-L1/2 derived peptides. 
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4.2 Results 
 
4.2.1 Bioinformatics research in type 1 RIPs from P. dioica 
 
The sequence of PD-L1/2 was analysed by using a previously described tool for the 
detection of cryptic HDPs [19]. The isometric plot, which correlates the predicted antimicrobial 
“absolute score” (AS) to all the possible peptides of length between 18 and 40 residues in the 
primary structure of PD-L1/2, shows two local maxima corresponding to peptides 50-79 (AS = 7.3-
7.5) and 50-71 (AS = 6.8-7.0). These scores correspond approximately to predicted MIC values in 
the range 10-40 µM. On the basis of this analysis, we selected for the characterization peptides 50-
73 and 50-80 (Figure 1), herein called IKY23 and IKY31, respectively. The small polar residues 
Asn72 and Ser80 were included at the C-termini of IKY23 and IKY31, respectively, in order to 
avoid that the negatively charged C-termini of the peptides were close to the antimicrobial region 
[21]. 
 
 
Figure 1. PD-L1/2 structure and PD-L1/2 derived peptides primary structures. A. Crystallographic structure 
of PD-L1/2 (PDB code: 3H5K). IKY31 and IKY23 are highlighted in red and yellow, respectively; B. 
Primary structures of both PD-L1/2 derived peptides. Cationic residues are in blue; glutamine and asparagine 
are in red. 
 
 
4.2.2 Antibacterial activity 
 
In order to evaluate the antibacterial activity of IKY23 and IKY31 peptides, 
antimicrobial assays were carried out on a panel of Gram-negative and Gram-positive bacterial 
strains, including Escherichia coli ATCC 25922 and Enterococcus faecalis ATCC 29212 (Table 1). 
Although PD-L1/2 derived peptides share a very similar amino acidic composition (Fig. 1), 
obtained MIC values highlighted that their antibacterial selectivity and potency are significantly 
different. Indeed, IKY23 exhibited a broad spectrum antimicrobial activity against both Gram-
positive and Gram-negative bacteria, with MIC values similar to those obtained for control peptide 
(P)GKY20 [22] against E. coli (MIC =12.5 µM) and S. aureus (MIC = 6.25 µM) strains. In 
contrast, IKY31 displayed selective antibacterial activity against Gram-positive bacteria with MIC 
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values of 25 µM and 50 µM versus S. aureus and E. faecalis, respectively.  Moreover, IKY31 was 
found to be ineffective against K. pneumoniae and P. aeruginosa strains, at least in our 
experimental conditions. It is worth noting that both bacterial strains are also strong biofilm 
producers. Bacteria living in biofilm growth mode are usually refractory to most conventional 
antibiotics, but they have been found to be sensitive to several HDPs, even at sub-MIC 
concentrations [23, 24]. Thus, we investigated PD-L1/2 derived peptides anti-biofilm properties 
against K.pneumoniae and P.aeruginosa strains. 
 
  
Compound 
MIC   
E. coli K. pneumoniae P. aeruginosa S. aureus E. faecalis B. spizizenii 
  
IKY31 
  
100 
  
>100 
  
>100 
  
25 
  
50 
  
50 
  
IKY23 
  
12.5 
  
50 
  
50 
  
6.25 
  
25 
  
50 
  
(P)GKY20
a
 
  
12.5 
  
12.5 
  
25 
  
6.25 
  
6.25 
  
50 
  
Polymyxin B
b
 
  
1  
  
1 
  
1 
  
>32 
  
>32 
  
>32 
  
Vancomycin
b
 
  
>32 
  
>32 
  
>32 
  
1 
  
>32 
  
4 
a
Values expressed in µM 
b
Values expressed in µg/mL 
 
 
 
Table 1. Antibacterial activity of PD-L1/2 derived peptides from Phytolacca dioica L. Assays were carried 
out by broth microdilution method in Nutrient Broth 0.5 X. MIC value shown are the highest values obtained 
from three independent experiments. 
 
4.2.3 Anti-biofilm activity  
 
To assess whether PD-L1/2 derived peptides affect bacterial biofilms, we first measured 
by crystal violet (CV) staining, the percentage of biofilm biomass formed in the absence or in the 
presence of increasing concentrations of each peptide (Fig. 2). We observed a dose-dependent 
reduction in biofilm biomass of P. aeruginosa and K. pneumoniae biofilms upon treatment with 
increasing concentrations of IKY31 (Fig. 2A) or IKY23 (Fig. 2B). 
We also determined the minimum biofilm inhibitory concentration, i.e. peptide concentration 
determining 50% biofilm reduction (MBIC50). We found that the MBIC50 for IKY31 was about 5 
µM against P. aeruginosa and about 0.6 µM against K. pneumoniae (Fig. 2A). Interestingly, it 
should be noted that peptide IKY31 exerted anti-biofilm activity even against bacterial strains that 
are not sensitive to peptide direct killing activity against planktonic cells (MIC >100 µM, Table 1). 
Using the same experimental set-up, peptide IKY23 was found to exert anti-biofilm activity, with 
MBIC50 values of about 50 µM and about 0.8 µM against P. aeruginosa PAO1 and K. pneumoniae, 
respectively (Fig. 2B). It has been previously reported that different peptides exhibiting low 
bactericidal activity are strong anti-biofilm agents. This may be due to peptide self-aggregation, a 
phenomenon shown to contribute to anti-biofilm activity [25], or may alternatively be mediated by 
several mechanisms of action [26].  
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In order to further investigate the anti-biofilm properties of PD-L1/2 derived peptides, we 
also performed analyses using confocal microscopy. First, we analysed the effects of both PD-L1/2 
derived peptides at sub-MIC concentrations (12.5 µM) on K. pneumoniae and P. aeruginosa 
biofilms. Incubations were carried out for 24 h at 37 °C in static conditions. Following incubation, 
chambers were double stained (Syto9/PI mix), in order to discriminate between live and dead 
biofilm cells. As shown in Fig. 3A, both peptides affected K. pneumoniae biofilm thickness. 
Indeed, the biofilm height of samples treated with IKY31 or IKY23 was reduced to about 16 µm 
and 22 µm, respectively, which was significantly lower than the value determined for the untreated 
sample (about 35 µm). Moreover, samples treated with IKY31 displayed a significant increase in 
cell death (Fig.3A, middle panels) together with reduced cell cohesion, which may be indicative of 
a disrupted extracellular matrix. On the other hand, treatment with peptide IKY23 led to decreased 
biofilm coverage (Fig.3A, bottom panels), although it did not dramatically reduce the number of 
adherent cells, which was found to be similar to that of the untreated control sample (Fig.3A, top 
panels). We also analysed the effect of both peptides against P. aeruginosa PAO1 biofilm 
formation (Fig. 3B). In this case, only the longest PDL1/2 derived peptide induced cell death, as 
indicated by the higher percentage of PI positive cells (Fig.3B, middle panels) with respect to 
control sample (Fig. 3B, top panels). However, in this case, no obvious biofilm morphology 
alterations were recorded in the presence of peptide. 
Altogether, these results indicate that both peptides significantly affect K. pneumoniae biofilm 
formation, in agreement with the crystal violet data obtained using the static microtiter plate assay. 
However, on the basis of our observations, it is possible to hypothesize that PD-L1/2 derived 
peptides exert their effects through different mechanisms of action. Collectively, the longest peptide 
(IKY31) seem to exert its anti-biofilm effects through an anti-adhesive mode of action, likely 
mediated by an alteration of the biofilm structural components (e.g., those within the biofilm 
extracellular matrix). Since biofilm matrix components of P. aeruginosa PAO1 are well-
characterized and, as described above, no remarkable biofilm morphology alterations were recorded 
when biofilms were grown under static conditions, we next investigated the anti-biofilm properties 
of PD-L1/2 derived peptides against P. aeruginosa PAO1 cells by using a more sensitive flow cell 
device apparatus. This system enables continuous monitoring of biofilm formation over time and 
thus constitutes an excellent platform for screening and identifying novel compounds endowed with 
biofilm detachment activity [27, 28]. PDL1/2 derived peptides were tested for their ability to 
eradicate 2-day-old pre-formed biofilm of the human pathogenic Gram-negative P. aeruginosa 
PAO1. As shown in Fig. 4, both peptides induced cell death when compared to the untreated 
control, as indicated by increased PI uptake into cells, which correlates with an altered membrane 
permeability. Interestingly, treatment with each peptide affected the biofilm mode of growth 
compared to the untreated control. Indeed, IKY23 substantially decreased adherent cells (Fig. 4, 
middle panels), whereas IKY31 (Fig. 4, bottom panels) reduced biofilm microcolonies, when 
compared to the untreated control (Fig.4, top panels). 
These results suggest that the longest peptide (IKY31) might be able to interfere with cell-to-cell 
cohesion and aggregation, a key feature of biofilm growth. In order to evaluate the effect of PD-
L1/2 derived peptides on structural biofilm features, we performed interaction studies with the 
exopolysaccharide alginate, an important component of the P. aeruginosa PAO1 extracellular 
biofilm matrix (see paragraph 4.3.3). 
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Figure 2. Biofilm biomass of wild-type P. aeruginosa PAO1 and K. pneumoniae ATCC 700603 upon 
treatment with PD-L1/2 derived peptides. Biofilms were grown at 37 °C for 48 h in the presence of 
increasing concentrations of IKY31 (A) or IKY23 (B), respectively. Biofilm growth was assessed by 0.1% 
crystal violet (w/v) staining and quantified at 595 nm. Data shown are the average values of experiments 
repeated twice independently ±SEM of biofilm mass percentage compared to biofilm mass growth in the 
absence of peptides. 
 
 
 
Figure 3. Analysis of the effect of PD-L1/2 derived peptides on static biofilm growth by CLSM 
imaging. A) K. pneumoniae ATCC 700603 and P.aeruginosa PAO1 wild type (B) untreated biofilm grown 
for 24 h in chambered coverglass slides (control) or in the presence of IKY31 (middle panels) or IKY23 
(bottom panels). Biofilm cells were stained by using LIVE/DEAD BacLight bacterial viability kit (Molecular 
Probes, Eugene, OR) containing 1:1 ratio of Syto-9 (green fluorescence, all cells; center panel) and 
propidium iodide (PI; red fluorescence, dead cells; left panel). Images are 2D projections of biofilm structure 
obtained by confocal z-stack using Zen Lite 2.3 software. All images were taken under identical conditions. 
Scale bar correspond to 10 μm in all the cases.  
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Figure 4. Anti-biofilm flow cell assays. Biofilm cells were stained by using a LIVE/DEAD 
BacLight bacterial viability kit (Molecular Probes, Eugene, OR) or Syto-9 alone prior to the 
microscopy experiments. A ratio of Syto-9 (green fluorescence, all cells; center panel) to propidium 
iodide (PI; red fluorescence, dead cells; left panel) of 1:1 was used. Microscopic analyses were 
performed by using a confocal laser-scanning microscope (Zeiss LSM 700 Laser Scanning 
Confocal), and three dimensional reconstructions were generated using the Imaris software package 
(Bitplane AG). Representative images out of two independent experiments are shown. Each panel 
shows reconstructions from the top in the large panel and sides in the right and bottom panels (xy, 
yz and xz dimensions). Scale bars correspond to 20 μm in all the cases. 
 
 
4.2.4 Secondary structure determination 
 
PD-L1/2 derived peptides conformation was characterized by circular dichroism (CD) 
spectroscopy. CD spectra were recorded in 10 mM sodium phosphate buffer pH 7.4, in the presence 
of increasing concentrations of TFE in phosphate buffer (10-30-50-70%) and in the presence of 20 
mM SDS. TFE is commonly used to induce alpha-helical structure and to stabilize protein 
secondary structure, whereas SDS, being an anionic detergent, forms micelles in aqueous solution at 
appropriate concentrations, thus mimicking bacterial membranes. 
Far-UV CD spectra recorded in phosphate buffer show negative peaks at ≈200 nm (Fig. 5), 
indicating that IKY23 and IKY31 are largely unstructured in absence of any likely interactor. 
However, in the presence of increasing concentrations of TFE (from grey to black line), a 
conformational change occurred for both peptides, as evidenced by the appearance of new minima 
at around 208 nm and 222 nm, indicative of a typical helical structure. 
The same conformation was induced also by 20 mM SDS (blue line) in the case of IKY31, whereas 
alpha helical content was found to be lower in the case of IKY23. This indicates that, upon 
interaction with membrane-mimicking agents, PD-L1/2 derived peptides are prone to assume an 
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alpha helical conformation, even if the effect was found to be less pronounced in the case of IKY23 
peptide. 
Since both peptides are endowed with antibacterial and antibiofilm activities, even if with 
differences in selectivity and potency, we also evaluated the effects on peptides secondary structure 
induced by LPS, a key molecule in Gram negative bacteria outer membrane, and alginate, is one of 
the main exopolysaccharides in PAO1 biofilm extracellular matrix [29].  
As shown in Fig. 5, in the presence of 0.2 mg/mL of LPS (green line), CD spectra showed a strong 
negative band at ≈216 nm, indicative of a beta sheet conformation. This was observed in the case of 
both peptides, although the effect was less pronounced for IKY23. A similar pattern was observed 
for both peptides when dichroic spectra were recorded in the presence of 0.2 mg/mL alginate (red 
line). In this case, a negative band switches from ≈216 nm (green line) to a ≈ 220 nm (red line). 
Taken together, CD data indicate that IKY23 and IKY31 conformations are altered by 
environmental factors. This might explain their different effects towards planktonic and sessile 
cells. 
 
 
 
Figure 5. CD spectra of IKY23 (A) and IKY31 (B) under different conditions. Far-UV spectra 
(wavelength from 190 to 260 nm) were recorded in the presence of phosphate buffer (dashed line), 
increasing concentrations of TFE (grey line), 20 mM SDS (blue line), 0.2 mg/mL LPS (green line) and 0.2 
mg/mL alginate (red line). 
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4.2.5 LPS binding assay  
 
Analyses by circular dichroism indicated that both PD-L1/2 derived peptides are able to 
interact with Gram-negative lipopolysaccharide. Hence, binding to LPS might play a crucial role in 
peptides antibacterial and anti-biofilm activity, since IKY23 mostly inhibits K. pneumoniae and 
P.aeruginosa PAO1 planktonic cells growth, whereas IKY31 exerts a strong anti-biofilm activity 
on both strains. Although several mechanisms of action might mediate peptides effects, it has been 
widely reported that many HDPs act via LPS neutralization [30]. On the other hand, LPS play a 
crucial role in determining cell-to-cell interactions in biofilm matrices [31]. 
On the basis of these observations, we examined PD-L1/2 derived peptides ability to neutralize 
LPS. To this purpose, we used the Limulus amebocyte lysate assay, which allows detection of traces 
of free LPS. Free LPS from Pseudomonas aeruginosa P10 was used as a positive control. The same 
amount of LPS was incubated with IKY23 or IKY31 (25 µM) for 30 minutes at 37 °C. As shown in 
Fig. 6, in the presence of both peptides, a significant reduction of free LPS amount was detected. 
However, IKY23 seems to be slightly more efficient, in agreement with data indicating that 
planktonic Gram-negative bacterial cells are more susceptible to this peptide rather than to IKY31. 
On the other hand, in the case of IKY31 peptide, the ability to neutralize LPS could concur to its 
anti-biofilm activity.  
 
 
 
Figure 6. LAL assay to determine IKY23 and IKY31 binding to LPS. Commercial LPS from 
Pseudomonas aeruginosa P10 was used to induce a colorimetric reaction (grey bar). Each PD-L1/2 derived 
peptide (25 μM) was pre-incubated at 37° C with 12.5 ng/mL LPS for 30 minutes. 
 
 
4.2.6 Cytotoxicity assays 
 
Since HDPs are gaining increasing attention as promising antimicrobial compounds, it 
is fundamental to demonstrate their selectivity of action and to exclude any possible toxic effects on 
mammalian cells.  PD-L1/2 derived peptides cytotoxicity was evaluated in vitro on human CaCo-2, 
HaCat and HeLa cell lines at three different incubation times (24, 48 and 72 h). As shown in Fig. 7, 
cytotoxicity of both peptides on CaCo2 or HaCat cells was negligible. Indeed, even at the highest 
concentration tested (100 µM), the percentage of viable cells was found to be higher than 90% even 
upon 72 h incubation. Similar results were obtained on HeLa cells as well (data not shown). 
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Figure 8. Effect of IKY23 and IKY31 peptides on eukaryotic cell viability. Cytotoxicity of PD-
L1/2 derived peptides on CaCo2 and HaCaT cells was evaluated at three different incubation times 
(24, 48 and 72 h), and reported on the left and on the right columns, respectively. In all the 
experiments, the mean values ± SD from three independent experiments run in triplicate are shown. 
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4.3 Conclusions 
Plants produce a diverse array of small proteins (less than 100 amino acid residues), 
most of which are cysteine-rich peptides (CRPs) that inhibit bacterial and fungal growth in vitro 
[32]. In plants, HDPs are mainly classified into cyclotides, defensins, thionins, lipid transfer 
proteins, snakins, and hevein-like vicilin-like and knottins. Plant hormones – gibberellins, ethylene, 
jasmonates, and salicylic acid, are among the physiological regulators that regulate the expression 
of HDPs. However, as widely reported in the literature, it is not to be ruled out that larger proteins 
that are not directly related to host defense can release, by proteolysis, small peptides with 
antibacterial activity. 
Indeed, in a previous report, our group identified by chemical fragmentation, and 
characterized the first cryptic HDP hidden in PD-L4, a type 1 RIP from leaves of P. dioica [33]. 
Here, we identified, by using a recently described bioinformatic tool, a putative host defence region 
in the N-terminal domain of PD-L1/2, another member of the differently expressed pool of type 1 
RIPs from P. dioica. Starting from this finding, two peptides contained in this region, here named 
IKY31 and IKY23, have been designed and synthesized, in order to structurally and functionally 
characterize them. Collected data indicate that both PD-L1/2 derived peptides exhibit antibacterial 
activities, even if with some differences. IKY23 exert its antibacterial activity with MIC values 
comparable to those of control peptide GKY20, whereas IKY31 seems to possess antimicrobial 
propensity only on planktonic Gram-positive bacteria. Since IKY31 is ineffective towards some 
Gram-negative bacteria, that are strong biofilm producers, it seemed interesting to verify if PD-L1/2 
derived peptides showed the same antimicrobial trend highlighted on planktonic cells also on sessile 
bacteria forming biofilm. Interestingly, we provided evidences that IKY23 and IKY31 are able to 
induce a strong dose-dependent reduction in biofilm biomass with MBIC values lower than those 
obtained on planktonic cells.  
Moreover, we found that PD-L1/2 derived peptides are also able to affect biofilm thickness 
and, in particular, the longest peptide (IKY31) seems to exert its anti-biofilm activity through an 
anti-adhesive mode of action, likely mediated by an alteration of the biofilm structural components. 
This suggests that IKY31 peptide might be able to interfere with cell-to-cell cohesion and 
aggregation, a fundamental event in biofilm expansion. Interestingly, on the basis of these 
observations, PD-L1/2 derived peptides may be classified as effective anti-biofilm agents, to be 
used as an efficient alternative to conventional antimicrobial agents, often ineffective on bacterial 
biofilm. 
A key feature of membranolytic and anti-biofilm agents is their selectivity towards 
prokaryotic systems. To verify this, we performed experiments which stated that PD-L1/2 derived 
peptides specifically bind to prokaryotic membrane components and, at the same time, they are 
innocuous for eukaryotic cells. In agreement with the canonical properties of most HDPs, circular 
dichroism analyses indicated that these RIP derived peptides are unstructured in aqueous buffer, 
whereas they tend to assume a specific conformation in the presence of increasing concentrations of 
TFE and of a membrane mimicking agent, such as SDS. In addition, dichroic spectra also indicated 
that the conformation of both PD-L1/2 derived peptides is influenced by LPS and alginate, which 
might be indicative of a binding probably mediating the effects of the two peptides on sessile and 
planktonic bacteria.  
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Overall, the data herein collected also suggest the intriguing hypothesis that this consensus 
active region, also found in different members of type 1 RIPs, could play a rather important role in 
the host-pathogen relationship in plants. Indeed, during delicate physio-pathological processes, 
proteolytic events, induced by host and/or by plant, might promote the release of bioactive peptides, 
similar to IKY31 and IKY23, able to modulate the immune response.  
As future perspective and application has been proposed, intriguingly, that transgenically 
produced HDP-plants will become a means showing that HDPs are able to mitigate host defense 
responses while providing durable resistance against pathogens. [34] 
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4.4 Experimental procedures 
 
4.4.1 Bacterial strains  
 
Bacterial strains used in this study were: Escherichia coli ATCC 25922, Enterococcus 
faecalis ATCC 29212 and Klebsiella pneumoniae ATCC 700603 (kindly provided by Dr. Eliana De 
Gregorio), wild-type Pseudomonas aeruginosa PAO1 (kindly provided by Dr. Donatella De 
Pascale) and Staphylococcus aureus ATCC 6538P (kindly provided by Prof. Mario Varcamonti). 
 
 
4.4.2 Antimicrobial activity assay 
 
The antimicrobial activity of PD-L1/2 derived peptides against planktonic bacteria was 
evaluated by broth microdilution method, performed as previously described for HDPs [35] with 
minor modifications. Peptides were dissolved in sterile water, and their concentration was 
determined by bicinchoninic acid colorimetric assay (Pierce™ BCA Protein Assay). Peptides were 
dispensed into aliquots (200 µM) and stored at -20°C until use. Antimicrobial assays were carried 
out in sterile 96-well polypropylene microtiter plates (Costar Corp., Cambridge, MA). Bacteria 
from an over-night culture were diluted in Nutrient broth (Difco, Becton Dickinson, Franklin Lakes, 
NJ) to a final concentration of 3-5 x 10
5
 CFU/mL per well in the presence of two-fold serial 
dilutions of IKY23, IKY31, or (P)GKY20 peptide, respectively. (P)GKY20 peptide is a short 
cationic HDP derived from the C-terminus of human thrombin [36], here used as a positive control. 
In all the cases, two-fold serial dilutions of antibiotics (polymyxin B and vancomycin) were tested 
as control. Plates were incubated at 37 °C for 24 h. The MIC (Minimum Inhibitory Concentration) 
values were determined as the lowest concentrations of different compounds at which no visible 
bacterial growth was observed.  
 
 
4.4.3 Microtiter plate biofilm assay 
 
Biofilm formation was analyzed by using a static abiotic solid surface assay, as 
previously described [28]. To this end, stationary phase wild-type Pseudomonas aeruginosa PAO1 
and Klebsiella pneumoniae ATCC700603 cells, obtained from an over-night culture, were diluted 
1/100 in BM2 adjusted medium (62 mM potassium phosphate buffer, pH 7.0, 7 mM (NH4)2SO4, 0.5 
mM MgSO4, 10 µM FeSO4) containing 0.4% (wt/vol) glucose as a carbon source. Assays were 
carried out in sterile 96-well polypropylene microtiter plates (Costar Corp., Cambridge, MA) in the 
presence of different concentrations of PD-L1/2 derived peptides or antibiotics (polymyxin B and 
vancomycin). Samples in the absence of peptides were used as a positive control, whereas samples 
in the absence of bacteria were used as a negative control. Following incubation at 37 °C for 48 h, 
samples were gently washed with water, in order to remove planktonic cells, whereas biofilm 
biomass was stained with 0.1% crystal violet (Sigma Aldrich, Milan, Italy). Biofilm stained 
biomass was transferred into flat-bottom plystyrene 96-well plate and optical densities at 595 nm 
were measured using a microtiter plate reader (Synergy™ H4 Hybrid Microplate Reader, BioTek 
Instruments, Inc., Winooski, Vermont, USA). MBIC50 values were determined as the lowest 
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concentration values determining 50% inhibition of biofilm formation with respect to the positive 
control. 
 
 
4.4.4 Confocal microscopy (CLSM) analysis of static biofilm growth 
 
Biofilms were grown into chambered coverglass slides (Nunc Lab-Tek, ThermoFisher 
Scientific, USA) in BM2 adjusted medium in static condition at 37 °C for 24 h. Bacterial cells from 
an over-night culture were diluted to about 2 x 10
9
 CFU/mL and 2 x 10
8
 CFU/mL for 
K.pneumoniae and P.aeruginosa PAO1, respectively, and seeded into wells of the chambers. After 
bacterial attachment for 4h at 37 °C, peptides were added to bacterial samples at a concentration of 
12.5 µM and incubated for further 20 h. Upon incubation, non-adherent bacteria were removed by 
gently washing samples with sterile phosphate buffer. Viability of cells embedded into biofilm 
structure was determined by sample staining with LIVE/DEAD
®
 BacLight™ Bacterial Viability kit 
(Molecular Probes ThermoFisher Scientific, USA), performed accordingly to manufacturer 
instructions. Biofilm images were captured by using a confocal laser scanning microscopy (Zeiss 
LSM 710, Zeiss, Germany) and a 63 X objective oil immersion system. Biofilm architecture was 
analysed by using the Zen Lite 2.3 software package. Each experiment was performed in triplicate. 
All images were taken under identical conditions. 
 
 
4.4.5 Biofilm cultivation in flow chambers and microscopy 
 
P.aeruginosa PAO1 biofilm was grown for 72 h in the absence or presence of each PD-
L1/2 derived peptide (3 μmol/L) at 37 °C in flow chambers (channel dimensions of 1 by 4 by 40 
mm) in BM2 minimal medium. Silicone tubing (inner diameter, 0.062 in.; outer diameter, 0.125 in.; 
wall thickness, 0.032 in.; VWR, Radnor, PA, USA) was used and the device was assembled and 
sterilized by pumping a 10% hypochlorite solution through the system for 5 min using a 
multichannel peristaltic pump. The system was then rinsed with sterile water and medium for 5 min 
for each channel. Flow chambers were inoculated by injecting 400 μL of wild-type P.aeruginosa 
PAO1 over-night culture diluted to an OD600nm  of approximately 0.05. After inoculation, chambers 
were left without flow for 3 h, after which medium was pumped through the system at a constant 
rate of 2.4 mL/h. Bacteria were allowed to develop structured 2-day-old biofilms prior to peptide 
treatment for the following 22 h. Biofilm cells were stained using a LIVE/DEAD BacLight bacterial 
viability kit (Molecular Probes, Eugene, OR, USA) using a  1:1 ratio of Syto-9 (green fluorescence, 
all cells) to propidium iodide (PI; red fluorescence, dead cells). Microscopy analyses were carried 
out using a confocal laser scanning microscope (Zeiss LSM 700 Laser Scanning Confocal), and 
three-dimensional reconstructions were generated using the Imaris software package (Bitplane AG). 
Experiments were performed twice with identical results. 
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4.4.6 Circular dichroism analyses 
 
Circular dichroism (CD) spectra of PD-L1/2 derived peptides were recorded with a J-
810 spectropolarimeter equipped with a Peltier temperature control system (Model PTC- 423-S; 
Jasco Europe, Cremella, LC, Italy). Far-ultraviolet (far-UV) measurements (190–260 nm) were 
carried out at 25 °C using a 0.1 cm optical path length cell and a peptide concentration of 35 μm. 
CD spectra, recorded with a time constant of 4 s, a 2 nm bandwidth, and a scan rate of 10 nm·min
−1
 
were signal-averaged over at least three scans. CD spectra were acquired in 10 mM sodium 
phosphate buffer pH 7.2 and in the presence of different concentrations of trifluoroethanol (TFE), 
20 mM SDS, 0.2 mg/mL LPS from Escherichia coli 0111:B4 and 0.2 mg/mL alginate. Estimation 
of the secondary structure was carried out accordingly to the Variable Selection Method (CDSSTR) 
using DICHROWEB, as previously described [37]. 
 
 
4.4.7 Peptide binding to lipopolysaccharide (LAL assay) 
 
The ability of PD-L1/2 derived peptides to neutralize LPS was determined by using the 
commercially available Limulus amebocyte lysate (LAL) assay (Pierce
®
 LAL Chromogenic 
Endotoxin Quantitation Kit, ThermoFisher Scientific, Waltham, MA, USA) (Park et al., 2009). 
Briefly, 25 μL of each peptide (25 µM) were added to 25 μl of 12.5 ng/mL Pseudomonas 
aeruginosa P10 LPS (Sigma Aldrich, Milan, Italy) for 30 min at 37 °C. Upon incubation, 50 μL of 
amebocyte lysate reagent were added to samples for 10 min. Absorbance values at 405 nm were 
measured 10 min after the addition of 100 μL of the chromogenic substrate, Ac-Ile-Glu-Ala-Arg-p-
nitroanilide.  
 
 
4.4.8 Cytotoxicity on mammalian cells  
 
Cytotoxicity towards normal (HaCat) or tumor (HeLa and CaCo-2) cells was assessed 
by performing the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) reduction 
inhibition assay [38]. Cytotoxicity experiments were performed at least four times independently. In 
all the cases, cells were grown for 24, 48 and 72 h in the absence or in the presence of increasing 
concentrations (0.6 to 100 μM) of each peptide. Cell survival values are expressed as percentage of 
viable cells with respect to control untreated samples.  
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Concluding remarks 
Host defense peptides (HDPs) are important modulators in both mammalian and non-
mammalian systems to prevent microbial colonization and tissue damage [1]. HDPs beneficial 
effects may encompass direct antimicrobial activity, binding to endotoxins, such as LPS or LTA, 
which reduce the detrimental pro-inflammatory response, and one or more direct effects on cellular 
behaviors, such as enhanced migration and proliferation. The majority of HDPs share common 
biochemical features, including relatively small size, cationicity and amphipathicity in membrane-
mimicking environments. These features allow them to selectively interact with and damage 
bacterial membranes. Several proteins contain HDPs hidden inside their sequence called cryptic 
peptides [2, 3, 4].                     
Further, it is noteworthy that cryptic peptides were identified in larger proteins involved in 
not only host defense, but also sequences with completely different roles. Therefore, such functional 
cryptic peptides that are hidden in protein structures are named “cryptides” in general [5]. 
The cryptome consists of bioactive peptides generated by the proteolysis of precursor 
proteins. It is speculated that the cryptide repertoire increases the complexity of the proteome by an 
order of magnitude. Recently discovered cryptides are involved in the regulation of a diverse range 
of cellular processes including neuronal signaling, the inflammatory response, the adaptive immune 
response, and angiogenesis. They are derived from many well-studied proteins, including 
hemoglobin, cytochromes, laminins, and collagen [6, 7, 8, 9, 10].  
Due to their potential as therapeutic agents, there has been an increasing interest in studying 
cryptides [11] as well as host defense peptides in particular.  
HDPs, as a novel class of antimicrobial therapeutics, give hope to confining the rise of 
antibiotic resistances and to acting as promising novel weapons against microbial pathogens. 
Despite the success to date in antimicrobial development, the inexorable, ongoing emergence of 
resistance worldwide continues to spur the search for novel anti-infectives to replace and/or 
supplement conventional antibiotics. Human defensins, cathelicidin, and a significant number of 
diverse HDPs from bacteria, viruses, plants, vertebrates, and invertebrates all appear to have a 
universal multidimensional signature (i.e., a common three-dimensional structure) that defines 
antimicrobial activity. Manipulation of this chemical structure to create designer synthetic peptides 
represents a promising strategy for the development of HDPs as a new class of drugs to prevent and 
treat systemic and topical infections. Regarding to HDPs, there are several different potential 
strategies for their general therapeutic application: (1) as single anti-infective agents, (2) in 
combination with conventional antibiotics or antivirals to promote any additive or synergistic 
effects, (3) as immune stimulatory agents that enhance natural innate immunity, and (4) as 
endotoxin-neutralizing agents to prevent the potentially fatal complications associated with bacterial 
virulence factors that cause septic shock.  
Unfortunately, of the potential pool of thousands of natural peptides and millions of 
synthetic peptide possibilities, relatively few have actually proceeded into clinical trials based on 
promising data from in vitro and animal studies. Despite a continuing optimism, the commercial 
success remains elusive. In 2004, a list of HDPs in clinical trials was published, and to date, none of 
the peptides described has obtained FDA (Food and Drug Administration) approval for their 
various clinical indications. Reasons of this lack could be found looking at some disadvantages of 
HDPs. In fact, although HDPs have considerable advantages for therapeutic applications, 
including broad-spectrum activity, rapid onset of activity, and relatively low possibility of 
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resistance emergence, they also have some limitations for drug development as low stability to 
pH changes and protease action as well as potential hemolytic properties. In order to overcome 
those obstacles, many methods have been proposed. For instances, introduction of unusual amino 
acids (mainly D-form amino acids) or modification of the terminal regions (acetylation or 
amidation) improved the stability of peptides by preserving them from proteolytic degradation. 
Also, the use of efficient drug delivery systems, such as liposome encapsulation, can be effective 
for the improvement of the stability and reduction of potential toxicity.  
Moreover, since they are able to interact in some cases with eukaryotic cell membranes, as 
well, HDPs could be used as delivery vectors for several bioactive compounds. However, despite all 
of the benefits that have emerged with the development of HDPs, researchers aim to face several 
shortcomings and to enhance their antibacterial activity and mode of action by various 
modifications, leading to functionalized HDPs and HDP conjugates. In fact, HDPs can be 
functionalized to generate peptide conjugates, in which various substances are attached by different 
coupling strategies. The potential of such new HDP compositions was recently summarized by 
Brogden et al. [12]: for instance, antibiotics coupled to HDPs or HDP-like sequences, improving 
HDP activity by lipidation, decoration of particles and polymers with HDPs, conjugates out of 
HDPs and organometallic complexes.  
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APPENDIX 
 
Abbreviations:  
 
HDP: host defence peptides; LPS: lipopolysaccharide; LTA: lipoteichoic acid; MIC: Minimum 
inhibitory concentration; SD: standard deviation; CD: circular dichroism; TFE: trifluoroethanol; 
IL-6: interleukin 6; NO: nitric oxide; CFU: colony forming unit; RBC: Red blood cell; HBTU: 2-
(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; Oxyma: cyano-
hydroxyimino-acetic acid ethyl ester; DIPEA: N,N′-diisopropylethylamine; TFA: trifluoroacetic 
acid; MeIm: 4-methylimidazole; MSNT : 1-(Mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole; DMF: 
N,N-Dimethylformamide; ACN: Acetonitrile; DCM: dichloromethane; Fmoc: 
fluorenylmethyloxycarbonyl; CATH-2: cathelicidin-2; TSA: Tryptic Soy Agar; AS: absolute score; 
MHB: Muller Hinton broth; NB: Nutrient Broth; MRSA: methicillin-resistant Staphylococcus 
aureus; VRE, vancomycin-resistant enterococci; AMPs: Antimicrobial Peptides; ApoE: 
apolipoprotein E; ApoB: apolipoprotein B; LDL: low-density lipoprotein; IL-10: interleukin-10; 
TSA: Tryptic Soy Agar; AS: absolute score; NB: Nutrient Broth; SDS: sodium dodecyl sulfate; 
FIC: Fractional Inhibitory Concentration; iNOS: nitric oxide synthase; CATH-2: cathelidin-2; 
PBS: phosphate-buffered saline; WH: wound healing. CNBr: Cyanogen bromide; Na/P: Sodium 
phosphate buffer; Tris•Cl:Tris(hydroxymethyl)aminomethane-HCl buffer; SEM: Standard Error of 
the Mean; LAL: Limulus amebocyte lysate; PI: propidium iodide; OD: optical density. 
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